

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptayvv1621

PASSWORD:

LOGINID/PASSWORD REJECTED

The loginid and/or password sent to STN were invalid.
You either typed them incorrectly, or line noise may
have corrupted them.

Do you wish to retry the logon?

Enter choice (y/N):

Do you wish to use the same loginid and password?

Enter choice (y/N):

Enter new loginid (or press [Enter] for ssptayvv1621):

Enter new password:

LOGINID:

LOGINID:ssptayvv1621

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAPLUS enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	OCT 27	Free display of legal status information in CA/CAPLUS, USPATFULL, and USPAT2 in the month of November.

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer

agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:21:46 ON 17 NOV 2009

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 16:21:56 ON 17 NOV 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2009 HIGHEST RN 1192511-54-8

DICTIONARY FILE UPDATES: 16 NOV 2009 HIGHEST RN 1192511-54-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>


Uploading C:\Program Files\Stnexp\Queries\10522716-Ie.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

SAMPLE SEARCH INITIATED 16:22:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 15992 TO ITERATE

6 ANSWERS

```

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   312264 TO   327416
PROJECTED ANSWERS:      544 TO     1374

```

=> s ll full

FULL SEARCH INITIATED 16:22:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 320315 TO ITERATE

```
100.0% PROCESSED      320315 ITERATIONS              1172 ANSWERS  
SEARCH TIME: 00.00.23
```


L3 1172 SEA SSS FUL L1

=> d scan 13

```
L3      1172 ANSWERS      REGISTRY  COPYRIGHT 2009 ACS on STN
IN      INDEX NAME NOT YET ASSIGNED
SQL     7
MF      C38 H64 N8 O15 S
```

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20



L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Yessotoxin, 1,4-di-O-desulfo-1,4-O-[24-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-
 thieno[3,4-d]imidazol-4-yl]-4,20-dioxo-7,10,13,16-tetraoxa-3,19-
 diazatetracos-1-ylidene]-
 MF C79 H122 N4 O22 S

PAGE 1-A








PAGE 2-A






L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Lutetate(3-)-177Lu, [[5,5'-[N-[1-oxo-17-thioxo-17-[[4-[[1,4,7,10-tetrakis[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-2-yl-κN1,κN4,κN7,κN10]methyl]phenyl]amino]-4,7,10,13-tetraoxa-16-azaheptadec-1-yl]-L-glutamoyl]bis[cyclo(L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-D-lysylato)]](6-)]-, hydrogen (1:3)
 SQL 11,5,5,1
 MF C94 H135 Lu N25 O29 S . 3 H
 CI CCS

RELATED SEQUENCES AVAILABLE WITH SEQLINK







****RELATED SEOUENCES AVAILABLE WITH SEOLINK****

PAGE 1-A

CCOCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)N[C@@H](C(=O)O)CC(=O)O

```
L3 1172 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN  Xanthylum, 3,6-diamino-9-[2-carboxy-4(or
   5)-[17-(2,6-dichlorophenoxy)-1,17-dioxo-5,8,11,14-tetraoxa-2-azaheptadec-1-
   yl]phenyl]-4,5-disulfo-, inner salt, compd. with N,N-diethylethanamine
   (1:2)
MF  C38 H37 Cl2 N3 O16 S2 . 2 C6 H15 N
```




L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN INDEX NAME NOT YET ASSIGNED
 SQL 9
 MF C100 H164 Gd N20 O32


CI CCS, COM

RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-A




PAGE 1-B




PAGE 2-A




PAGE 2-B




PAGE 2-C



PAGE 2-D




PAGE 2-E




L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Cyclo[N-(14-carboxy-3,6,9,12-tetraoxatetradec-1-yl)-L-asparaginyl-L-valyl-
 L-prolylglycyl-N-(14-carboxy-3,6,9,12-tetraoxatetradec-1-yl)-L-asparaginyl-
 L-valyl-L-prolylglycyl]
 SQL 8
 MF C54 H90 N10 O22

RELATED SEQUENCES AVAILABLE WITH SEQLINK


PAGE 1-A



PAGE 1-B




PAGE 1-C



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4,7,10,13,16,19-Hexaoxatricosanedioic acid,
21-amino-3-[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethoxy]methyl]-9-(1H-indol-3-ylmethyl)-6,15-bis[2-(methylthio)ethyl]-18-[[4-(sulfooxy)phenyl]methyl]-, (3S,6S,9S,15S,18S,21S)-
MF C49 H69 N3 O16 S3

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 1H-Thieno[3,4-d]imidazole-4-pentanamide,
 N-(22-azido-15-oxo-3,6,9,12-tetraoxa-16-azadocos-1-yl)hexahydro-2-oxo-,
 (3aS,4S,6aR)-
 MF C27 H49 N7 O7 S

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B





L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 3,6,9,12,15,18,24-Heptaosa-21-azahexacosanoic acid,
 26,26',26'',26'''-[21H,23H-porphine-5,10,15,20-tetrayltetrakis(4,1-
 phenyleneimino)]tetrakis-
 MF C116 H158 N12 O44


PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 1-D




PAGE 2-A



PAGE 2-B



PAGE 2-C




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN α -D-Glucopyranoside, methyl O-4-O-[(14S)-31-[3-[[[(1S)-1-carboxy-2-[4-[4-(4-piperidiny)l)butoxy]phenyl]ethyl]amino]sulfonyl]phenyl]-14-[4-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]methylamino]butyl]-12-methyl-13,16,31-trioxo-3,6,9,18,21,24,27-hepta-oxa-12,15,30-triazahentriacont-1-yl]-2,3-di-O-methyl-6-O-sulfo- α -D-glucopyranosyl-(1 \rightarrow 4)-O-2,3-di-O-methyl- β -D-glucopyranuronosyl-(1 \rightarrow 4)-O-2,3,6-tri-O-sulfo- α -D-glucopyranosyl-(1 \rightarrow 4)-O-2,3-di-O-methyl- α -L-idopyranuronosyl-(1 \rightarrow 4)-, 2,3,6-tris(hydrogen sulfate)
MF C97 H156 N8 O66 S9
CI COM


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Glycine, L-γ-glutamyl-S-[1-[(12S)-12-(aminocarbonyl)-41-
 [(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-6,14,30,37-
 tetraoxo-17,20,23,26-tetraoxa-7,13,29,36-tetraazahentetracont-1-yl]-2,5-
 dioxo-3-pyrrolidinyl]-L-cysteinyl-
 MF C53 H89 N11 O18 S2

Absolute stereochemistry.







PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 9,12,15,18-Tetraoxa-5,21-diazaheptatriacontanedioic acid,
 4-[(1,1-dimethylethoxy)carbonyl]-6,22-dioxo-, 37-(1,1-dimethylethyl)
 1-(2,5-dioxo-1-pyrrolidinyl) ester, (4S)-
 MF C44 H77 N3 O14

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 5,8,11,14,17,20-Hexaoxa-2-azatricosanedioic acid,
 1-(9H-fluoren-9-ylmethyl) ester
 MF C30 H41 N O10




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Benzo[1,2-b:4,3-b']dipyrrole-1-carboxylic acid,
 8-(chloromethyl)-4-[[[2-[(21,21-dimethyl-3,19-dioxo-7,10,13,16,20-
 penta-4-azadocos-1-yl)dithio]phenyl]methylamino]carbonyl]oxy]-3,6,7,8-
 tetrahydro-6-[(5-methoxy-2-benzofuranyl)carbonyl]-2-methyl-, methyl ester,
 (8S)-
 MF C50 H61 Cl N4 O14 S2

Absolute stereochemistry.







PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN L-Phenylalaninamide, N-[[[(3R)-1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]-L- α -aspartyl-N-(16,16-dimethyl-14-oxo-3,6,9,12,15-pentaoxaheptadec-1-yl)-(9CI)
 MF C41 H65 N5 O12


Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Heptanedioic acid, 4-[3-(1,1-dimethylethoxy)-3-oxopropyl]-4-[[[20-(1,2-dithiolan-3-yl)-1,16-dioxo-3,6,9,12-tetraoxa-15-azaeicos-1-yl]amino]-, 1,7-bis(1,1-dimethylethyl) ester
 MF C40 H72 N2 O12 S2

PAGE 1-A



PAGE 1-B







PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclo[L-arginylglycyl-L- α -aspartyl-D-phenylalanyl-N6-[N2-[3,5-bis(phosphonomethyl)benzoyl]-L-lysyl-L-lysyl-20-amino-3,6,9,12,15,18-hexaoxaeicosanoyl-20-amino-3,6,9,12,15,18-hexaoxaeicosanoyl]-L-lysyl]
(9CI)
SQL 9,5,4
MF C76 H129 N15 O30 P2

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.







PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 4,7,10,13-Tetraoxa-16-azaheneicosanoic acid,
 21-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-17-oxo-,
 hydrazide
 MF C21 H39 N5 O7 S



Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 1172 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 5,8,11,14,17-Pentaoxa-2-azanonadecanedioic acid, 1-(9H-fluoren-9-ylmethyl)
19-(phenylmethyl) ester
MF C34 H41 N O9






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3	1172 ANSWERS	REGISTRY	COPYRIGHT 2009 ACS on STN
IN	Cyclo[L-arginylglycyl-L- α -aspartyl-D-phenylalanyl-N-[(22S)-22-carboxy-20,25-dioxo-29-[4-(trimethylstannyl)phenyl]-3,6,9,12,15,18,27-hepta-oxa-21,24,28-triazanonacos-28-en-1-yl]-L-glutaminy]] (9CI)		
SQL	5		
MF	C55 H84 N12 O19 Sn		

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> s 5,8,11,14,17-Pentaoxa-2-azanonadecanedioic acid,  
1-(9H-fluoren-9-ylmethyl)-19-(phenylmethyl) ester  
MISSING OPERATOR '1-(9H-FLUOREN'
```

=> s (5,8,11,14,17-Pentaoxa-2-azanonadecanedioic acid,
1-(9H-fluoren-9-ylmethyl)-19-(phenylmethyl) ester)

=> d 15 ibib abs hitstr 1-30

L5 ANSWER 1 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:1199639 CAPLUS

TITLE: Long-Chain Alkylthiol Assemblies Containing Buried In-Plane Stabilizing Architectures

AUTHOR(S): Lee, Hung-Hsun; Ruzele, Zivile; Malysheva, Lyuba; Onipko, Alexander; Gutes, Albert; Bjoerefors, Fredrik; Valiokas, Ramunas; Liedberg, Bo

CORPORATE SOURCE: Division of Molecular Physics, Department of Physics, Chemistry and Biology, Linköping University, Linköping, 58183, Swed.

SOURCE: Langmuir ACS ASAP
CODEN: LANGD5; ISSN: 0743-7463

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of alkylthiol compds. were synthesized to study the formation and structure of complex self-assembled monolayers (SAMs) consisting of interchanging structural modules stabilized by intermol. hydrogen bonds. The chemical structure of the synthesized compds., HS(CH₂)₁₅CONH(CH₂CH₂O)₆CH₂CONH-X, where X refers to the extended chains of either -(CH₂)_nCH₃ or -(CD₂)_nCD₃, with n = 0, 1, 7, 8, 15, was confirmed by NMR and elemental anal. The formation of highly ordered, methyl-terminated SAMs on gold from diluted ethanolic solns. of these compds. was revealed using contact angle goniometry, null ellipsometry, cyclic voltammetry, and IR reflection absorption spectroscopy. The exptl. work was complemented with extensive DFT modeling of IR spectra and mol. orientation. New assignments were introduced for both nondeuterated and deuterated compds. The latter set of compds. also served as a convenient tool to resolve the packing, conformation, and orientation of the buried and extended modules within the SAM. Thus, it was shown that the lower alkyl portion together with the hexa(ethylene glycol) portion is stabilized by the two layers of lateral hydrogen bonding networks between the amide groups, and they provide a structurally robust support for the extended alkyls. The presented system can be considered to be an extension of the well-known alkyl SAM platform, enabling precise engineering of nanoscopic architectures on the length scale from a few to .apprx.60 Å for applications such as cell membrane mimetics, mol. nanolithog., and so forth.

IT 1191245-67-6P 1191245-69-8P 1191245-71-2P
1191245-73-4P 1191245-75-6P 1191245-78-9P
1191245-80-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(S-deprotection; long-chain alkylthiol assemblies containing buried in-plane stabilizing architectures)


RN 1191245-67-6 CAPLUS

CN Ethanethioic acid, S-(16,37-dioxo-20,23,26,29,32,35-hexaoxa-17,38-diazanonatriacont-1-yl) ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 1191245-69-8 CAPLUS

CN Ethanethioic acid, S-(16,37-dioxo-20,23,26,29,32,35-hexaoxa-17,38-diazatetracont-1-yl) ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 1191245-71-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1191245-73-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1191245-75-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1191245-78-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1191245-80-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




IT 352439-49-7
RL: PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)
(adsorbed on gold; cyclic voltammetry; long-chain alkylthiol assemblies containing buried in-plane stabilizing architectures)
RN 352439-49-7 CAPLUS

CN 3,6,9,12,15,18-Hexaoxa-21-azaheptatriacontanamide,
N-hexadecyl-37-mercapto-22-oxo- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




IT 1191245-70-1P 1191245-74-5P
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); RCT
 (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC
 (Process); RACT (Reactant or reagent)
 (adsorbed on gold; cyclic voltammetry; long-chain alkylthiol assemblies
 containing buried in-plane stabilizing architectures)
 RN 1191245-70-1 CAPLUS
 CN 5,8,11,14,17,20-Hexaoxa-2-azadocosanamide,
 N-ethyl-1-(15-mercaptopentadecyl)-1-oxo- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 1191245-74-5 CAPLUS
 CN 5,8,11,14,17,20-Hexaoxa-2-azadocosanamide,
 1-(15-mercaptopentadecyl)-N-octyl-1-oxo- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




IT 1191245-68-7P 1191245-72-3P 1191245-76-7P
 1191245-79-0P 1191245-81-4P
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN
 (Synthetic preparation); PREP (Preparation); PROC (Process)
 (adsorbed on gold; long-chain alkylthiol assemblies containing buried
 in-plane stabilizing architectures)
 RN 1191245-68-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1191245-72-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1191245-76-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 1191245-79-0 CAPLUS
 CN 5,8,11,14,17,20-Hexaoxa-2-azadocosanamide,
 1-(15-mercaptopentadecyl)-N-nonyl-1-oxo- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 1191245-81-4 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




IT 352439-47-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (amidation; long-chain alkylthiol assemblies containing buried in-plane
 stabilizing architectures)
 RN 352439-47-5 CAPLUS
 CN 3,6,9,12,15,18-Hexaoxa-38-thia-21-azatetracontanoic acid, 22,39-dioxo-
 (CA INDEX NAME)

PAGE 1-A




PAGE 1-B





ACCESSION NUMBER: 2002:808500 CAPLUS
 DOCUMENT NUMBER: 138:34814
 TITLE: Synthesis of the DNA-[Ru(tpy)(dppz)(CH₃CN)]²⁺
 conjugates and their photo cross-linking studies with
 the complementary DNA strand
 AUTHOR(S): Ossipov, Dimitri; Gohil, Suresh; Chattopadhyaya, Jyoti
 CORPORATE SOURCE: Biomedical Center, Department of Bioorganic Chemistry,
 University of Uppsala, Uppsala, S-751 23, Swed.
 SOURCE: Journal of the American Chemical Society (2002),
 124(45), 13416-13433
 CODEN: JACSAT; ISSN: 0002-7863
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 138:34814

AB We here report our studies on the conjugation of photoreactive Ru²⁺
 complex to oligonucleotides (ODNs), which give a stable duplex with the
 complementary target DNA strand. These functionalized DNA duplexes
 bearing photoreactive Ru²⁺ complex can be specifically photolyzed to give
 the reactive aqua derivative, [Ru(tpy)(dppz)(H₂O)]²⁺-ODN (tpy =
 2,2':6',2''-terpyridine; dppz = dipyrido[3,2-a:2',3'-c]phenazine), in
 situ, which successfully cross-links to give photoproduct(s) in the duplex
 form with the target complementary DNA strand. Thus, the stable precursor
 of the aquaruthenium complex, the monofunctional polypyridyl ruthenium
 complex [Ru(tpy)(dppz)(CH₃CN)]²⁺, has been site-specifically tethered to
 ODN, for the first time, by both solid-phase synthesis and postsynthetic
 modifications. (i) In the first approach, pure
 3'-[Ru(tpy)(dppz)(CH₃CN)]²⁺-ODN conjugate has been obtained in 42% overall
 yield (from the monomer blocks) by the automated solid-phase synthesis on
 a support labeled with [Ru(tpy)(dppz)Cl]⁺ complex with subsequent
 liberation of the crude conjugate from the support under mild conditions
 and displacement of the Cl⁻ ligand by acetonitrile in the coordination
 sphere of the Ru²⁺ label. (ii) In the second approach, the
 single-modified (3'- or 5'- or middle-modified) or 3',5'-bis-modified
 Ru²⁺-ODN conjugates were prepared in 28-50% yield by an amide bond formation
 between an active ester of the metal complex and the ODNs conjugated with
 an amino linker. The pure conjugates were characterized unambiguously by
 UV-visible (UV-vis) absorption spectroscopy, enzymic digestion followed by
 HPLC quantitation, PAGE, and mass spectrometry (MALDI-TOF as well as by
 ESI). [Ru(tpy)(dppz)(CH₃CN)]²⁺-ODNs form highly stabilized ODN·DNA
 duplexes compared to the unlabeled counterpart (ΔT_m varies from 8.4
 to 23.6°) as a result of intercalation of the dppz moiety; they
 undergo clean and selective photodissocn. of the CH₃CN ligand to give the
 corresponding aqua complex, [Ru(tpy)(dppz)(H₂O)]²⁺-ODNs (in the aqueous
 medium), which is evidenced from the change of their UV-vis absorption
 properties and the detection of the naked Ru²⁺-ODN ions generated in the
 course of the matrix-assisted laser desorption ionization time-of-flight
 (MALDI-TOF) mass spectrometric anal. Thus, when
 [Ru(tpy)(dppz)(CH₃CN)]²⁺-ODN conjugate was hybridized to the complementary
 guanine (G)-rich target strand (T), and photolyzed in a buffer (pH 6.8),
 the corresponding aqua complex formed in situ immediately reacted with the
 G residue of the opposite strand, giving the cross-linked product. The
 highest yield (34%) of the photo cross-linked product obtained was with
 the ODN carrying two reactive Ru²⁺ centers at both 3'- and 5'-ends. For
 ODNs carrying only one Ru²⁺ complex, the yield of the cross-linked adduct
 in the corresponding duplex is found to decrease in the following order:
 3'-Ru²⁺-ODN (22%) > 5'-Ru²⁺-ODN (9%) > middle-Ru²⁺-ODN (7%). It was also
 found that the photo cross-coupling efficiency of the tethered Ru²⁺
 complex with the target T strand decreased as the stabilization of the
 resulting duplex increased: 3'-Ru²⁺-ODN (VI·T) (ΔT_{mb} =
 7°) < 5'-Ru²⁺-ODN (V·T) (ΔT_{mb} = 16°) <



RN 478819-57-7 CAPLUS
 CN Ruthenium, chloro[mono[2-[bis(4-methoxyphenyl)phenylmethoxy]-1-[12-(dipyrido[3,2-a:2',3'-c]phenazin-11-yl-κN4,κN5)-12-oxo-2,5,8-trioxa-11-azadodec-1-yl]ethyl] butanedioato](2,2':6',2''-terpyridine-κN1,κN1',κN1'')-, (OC-6-43)- (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS
RECORD (17 CITINGS)
REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:798417 CAPLUS

DOCUMENT NUMBER: 138:250343

TITLE: Interactions of Inositol 1,4,5-Trisphosphate (IP3)
Receptors with Synthetic Poly(ethylene glycol)-linked
Dimers of IP3 Suggest Close Spacing of the IP3-binding
Sites

AUTHOR(S): Riley, Andrew M.; Morris, Stephen A.; Nerou, Edmund
P.; Correa, Vanessa; Potter, Barry V. L.; Taylor,
Colin W.

CORPORATE SOURCE: Department of Pharmacy and Pharmacology, Wolfson
Laboratory of Medicinal Chemistry, University of Bath,
Claverton Down, Bath, BA2 7AY, UK

SOURCE: Journal of Biological Chemistry (2002), 277(43),
40290-40295

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular
Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The distances between the inositol 1,4,5-trisphosphate (IP3)-binding sites
of tetrameric IP3 receptors were probed using dimers of IP3 linked by
poly(ethylene glycol) (PEG) mols. of differing lengths (1-8 nm). Each of
the dimers potentially stimulated 45Ca^{2+} release from permeabilized cells
expressing predominantly type 1 (SH-SY5Y cells) or type 2 (hepatocytes)
IP3 receptors. The shortest dimers, with PEG linkers of an effective
length of 1.5 nm or less, were the most potent, being 3-4-fold more potent
than IP3. In radioligand binding expts. using cerebellar membranes, the
shortest dimers bound with highest affinity, although the longest dimer (8
nm) also bound with almost 4-fold greater affinity than IP3. The affinity
of monomeric IP3 with only the PEG attached was 2-fold weaker than IP3,
confirming that the increased affinity of the dimers requires the presence
of both IP3 motifs. The increased affinity of the long dimer probably
results from the linked IP3 mols. binding to sites on different receptors,
because the dimer bound with greater affinity than IP3 to cerebellar
membranes, where receptors are densely packed, but with the same affinity
as IP3 to purified receptors. IP3 and the IP3 dimers, irrespectively of their
length, bound with similar affinity to a monomeric IP3-binding domain of
the type 1 IP3 receptor expressed in bacteria. Short dimers therefore
bind with increased affinity only when the receptor is tetrameric. We
conclude that the four IP3-binding sites of an IP3 receptor may be separated
by as little as 1.5 nm and are therefore likely to be placed centrally in
this large (25 + 25 nm) structure, consistent with previous work
indicating a close association between the central pore and the IP3-binding
sites of the IP3 receptor.

IT 502159-31-1P




RL: BSU (Biological study, unclassified); PNU (Preparation, unclassified);
BIOL (Biological study); PREP (Preparation)

(interactions of tetrameric IP3 receptors with synthetic PEG-linked
dimers of IP3 suggest close spacing of IP3-binding sites)

RN 502159-31-1 CAPLUS

CN D-myo-Inositol, 2,2'-O-(4,41-dioxo-6,9,12,15,18,21,24,27,30,33,36,39-
dodecaoxa-3,42-diazatetracontane-1,44-diyl)bis-,
1,1',4,4',5,5'-hexakis(dihydrogen phosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 21 THERE ARE 21 CAPLUS RECORDS THAT CITE THIS RECORD (21 CITINGS)

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:717763 CAPLUS

DOCUMENT NUMBER: 138:39852

TITLE: Water-soluble polymers with tunable temperature sensitivity: solution behavior

AUTHOR(S): Rackaitis, M.; Strawhecker, K.; Manias, E.

CORPORATE SOURCE: Department of Materials Science & Engineering, The Pennsylvania State University, University Park, PA, 16802, USA

SOURCE: Journal of Polymer Science, Part B: Polymer Physics (2002), 40(19), 2339-2342

CODEN: JPBPEM; ISSN: 0887-6266

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To design water-soluble polymers with a controlled temperature response in aqueous

OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS
RECORD (15 CITINGS)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:708816 CAPLUS
DOCUMENT NUMBER: 137:247925
TITLE: Preparation of peptide nucleic acid (PNA) containing
fluorescence and/or biotin-labeled puromycin
derivatives as their use for C-terminus monomolecular
labeling of proteins
INVENTOR(S): Sasaki, Akira; Nemoto, Naoto
PATENT ASSIGNEE(S): Gencom Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2002265492	A	20020918	JP 2001-65257	20010308
PRIORITY APPLN. INFO.:			JP 2001-65257	20010308
OTHER SOURCE(S):	MARPAT 137:247925			

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Puromycin derivs. [I; R = R1-L1-, X-L3-L2-L1-,
X1-L8-L7-L6-CH(-L5-L9-L10-L11-L12-L13-X2)-L4-L3-L2-L1-; wherein L1, L3,
L6, L9, L11, L13 = a spacer; L2, L4, L5, L7, L10, L12 = a linkage group;
R1 = a reactive group; Nu = pyrimidine or purine base residue such as
cytosine; X1, X2 = a residue of a labeling substance such as a
fluorescence substance] are prepared Also disclosed are protein or nucleic
acid or derivative thereof containing the compound I or its salt as the
constituent
component. Claimed is a method for preparation of modified protein or nucleic
acid involving a process of allowing the compound I or its salt to be taken
up into the protein or nucleic acid. The present patent establishes the
efficient synthesis of puromycin derivs. which are used to efficiently
label protein at the C-terminus, and a method for forming a complex of
nucleic acid and a protein coded by the nucleic acid using the puromycin
derivs. A protein introduced with the puromycin derivative I is typically
prepared by introducing RNA (preferably mRNA) coding the protein and the
puromycin derivative I into a transcription system and transcribing RNA into
protein. Thus, N-trifluoroacetylation of puromycin by trifluoroacetic
anhydride in pyridine/MeCN followed by tosylation with tosyl chloride in
pyridine gave N α -trifluoroacetyl-5'-O-tosyl puromycin which
underwent azidolysis with NaN₃ in DMSO at room temperature for 3 days to give
N α -trifluoroacetyl-5'-azido-5'-deoxy puromycin (II). Reduction of II to
N α -trifluoroacetyl-5'-amino-5'-deoxy puromycin by treatment with
Ph₃P and H₂O in pyridine followed by condensation with
N-[2-(4-methoxytritylamino)ethyl]-N-[[N₄-(4-tert-butylbenzoyl)cytosin-1-
yl]acetyl]glycine pentafluorophenyl ester in 0.15 M NaHCO₃/Na₂CO₃ buffer
and deprotection with NH₃ in aqueous EtOH and then with CF₃CO₂H gave I (R =
H₂N-CH₂CH₂, Nu = cytosin-1-yl) which was condensed with FluoroLink Mono
Reactive Dye Cy5 to give I (R = Q) (Cy5-C-amPu). mRNA coding green
fluorescein protein (GFP) (1 μ g) and 10 μ M I (R = Q) were added to

50 μ L of a wheat germ noncellular translation system (Promega) and allowed to react for 1 h. It was confirmed by separation of the protein using SDS-polyacrylamide electrophoresis and detecting the both fluorescein from I (R = Q) and GFP that the GFP synthesized was labeled by I (R = Q).

IT 459426-24-5P

RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptide nucleic acid (PNA) containing fluorescence and/or biotin-labeled puromycin derivs. as use for C-terminus monomol.


labeling of proteins and nucleic acids by translation of RNA into proteins)



RN 459426-24-5 CAPLUS


CN Adenosine, 3'-[[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-5'-[[[(4-amino-2-oxo-1(2H)-pyrimidinyl)acetyl][2-[N-[21-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1,17-dioxo-4,7,10,13-tetraoxa-16-azaheneicos-1-yl]- β -alanyl-N6-[6-[2-[(1E,3E,5E)-5-(1-ethyl-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene)-1,3-pentadienyl]-3,3-dimethyl-5-sulfo-3H-indol-1-yl]-1-oxohexyl]-L-lysyl- β -alanyl]amino]ethyl]amino]acetyl]amino]-3',5'-dideoxy-N,N-dimethyl-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A









IT 459426-22-3, (+)-Biotin-PEO4-NHS-propionate
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of peptide nucleic acid (PNA) containing fluorescence and/or
 biotin-labeled puromycin derivs. as use for C-terminus monomol.
 labeling of proteins and nucleic acids by translation of RNA into
 proteins)
 RN 459426-22-3 CAPLUS
 CN 4,7,10,13-Tetraoxa-16-azaheneicosanoic acid,
 21-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-17-oxo-,
 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 459426-23-4P 459426-25-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of peptide nucleic acid (PNA) containing fluorescence and/or
 biotin-labeled puromycin derivs. as use for C-terminus monomol.
 labeling of proteins and nucleic acids by translation of RNA into
 proteins)
 RN 459426-23-4 CAPLUS
 CN Adenosine, 3'-[[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-5'-
 [[[(4-amino-2-oxo-1(2H)-pyrimidinyl)acetyl][2-[N-[21-[(3aS,4S,6aR)-
 hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1,17-dioxo-4,7,10,13-
 tetraoxa-16-azaheneicos-1-yl]-β-alanyl-L-lysyl-β-
 alanyl]amino]ethyl]amino]acetyl]amino]-3',5'-dideoxy-N,N-dimethyl- (9CI)



(CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 459426-25-6 CAPLUS

CN Adenosine, 3'-[[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-5'-[[[(4-amino-2-oxo-1(2H)-pyrimidinyl)acetyl][2-[N-[21-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1,17-dioxo-4,7,10,13-tetraoxa-16-azaheneicos-1-yl]-β-alanyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-β-alanyl]amino]ethyl]amino]acetyl]amino]-3',5'-dideoxy-N,N-dimethyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.





OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L5 ANSWER 6 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:323803 CAPLUS

DOCUMENT NUMBER: 137:95544

TITLE: Surface activities of disodium polyoxyalkylene fatty acid monoethanolamide sulfosuccinates

AUTHOR(S): Wu, Jin-Chuan; Zhuang, Yan; Tu, Yu-En

CORPORATE SOURCE: Chemical Engineering Research Center, Tianjin University, Tianjin, 300072, Peop. Rep. China

SOURCE: Tenside, Surfactants, Detergents (2002), 39(1), 39-41
CODEN: TSDEES; ISSN: 0932-3414

PUBLISHER: Carl Hanser Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

Disodium polyoxyethylene (POE) and polyoxypropylene (POP) fatty acid (C12 and C14) monoethanolamide sulfosuccinates were prepared and some of their surface activities were investigated. With increase in the polymerization

(m) of the oxyalkylene groups or in the number of carbon atoms (n) in the alkyl group of the fatty acids, the critical micelle concentration (c.m.c.) decreased and the surface tension at c.m.c. ($\gamma_{c.m.c.}$) increased.

The wetting power of the POE type was sharply reduced with increase in m while that of the POP type was slightly enhanced. The foaming capacity of both POE and POP types decreased with increase of m or n while their foam stability was less affected. The c.m.c. of the POE type was higher than that of the POP type at the same n and m values, while the $\gamma_{c.m.c.}$ of the former was lower than that of the latter. The wetting power of the former was inferior to that of the latter, while their difference in foam properties was insignificant.

IT	441778-79-6	441778-80-9	441778-82-1
	441778-83-2	442155-93-3	442155-94-4
	442155-95-5	442155-97-7	442155-98-8
	442155-99-9		


RL: PRP (Properties)

(surface activities of disodium polyoxyalkylene fatty acid monoethanolamide sulfosuccinates)


RN 441778-79-6 CAPLUS

CN Butanedioic acid, sulfo-, 4-(19-oxo-3,6,9,12,15-pentaoxa-18-azatriacont-1-yl) ester, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A

 $\bullet_2 \text{ Na}$


PAGE 1-B




RN 441778-80-9 CAPLUS

CN Butanedioic acid, 2-sulfo-, 4-(34-oxo-3,6,9,12,15,18,21,24,27,30-decaoxa-33-azapentatetracont-1-yl) ester, sodium salt (1:2) (CA INDEX NAME)


PAGE 1-A

 $\bullet_2 \text{ Na}$

PAGE 1-B





PAGE 1-C




RN 441778-82-1 CAPLUS

CN Butanedioic acid, sulfo-, 4-(19-oxo-3,6,9,12,15-pentaoxa-18-azadotriacont-1-yl) ester, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 441778-83-2 CAPLUS

CN Butanedioic acid, 2-sulfo-, 4-(34-oxo-3,6,9,12,15,18,21,24,27,30-decaoxa-33-azaheptatetracont-1-yl) ester, sodium salt (1:2) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 1-C



RN 442155-93-3 CAPLUS

CN Butanedioic acid, sulfo-, 4-(pentamethyl-19-oxo-3,6,9,12,15-pentaoxa-18-azatriacont-1-yl) ester, disodium salt (9CI) (CA INDEX NAME)


PAGE 1-A



5 (D1-Me)




PAGE 1-B



RN 442155-94-4 CAPLUS

CN Butanedioic acid, sulfo-, 4-(octamethyl-28-oxo-3,6,9,12,15,18,21,24-octaoxa-27-azanonatriacont-1-yl) ester, disodium salt (9CI) (CA INDEX NAME)


PAGE 1-A




8 (D1-Me)



PAGE 1-B




PAGE 1-C



RN 442155-95-5 CAPLUS

CN Butanedioic acid, sulfo-, 4-(decamethyl-34-oxo-3,6,9,12,15,18,21,24,27,30-decaoxa-33-azapentatetracont-1-yl) ester, disodium salt (9CI) (CA INDEX NAME)


PAGE 1-A




10 (D1-Me)

●2 Na

PAGE 1-B




PAGE 1-C



RN 442155-97-7 CAPLUS

CN Butanedioic acid, sulfo-, 4-(pentamethyl-19-oxo-3,6,9,12,15-pentaoxa-18-azadotriacont-1-yl) ester, disodium salt (9CI) (CA INDEX NAME)


PAGE 1-A



5 (D1-Me)

●2 Na


PAGE 1-B



RN 442155-98-8 CAPLUS

CN Butanedioic acid, sulfo-, 4-(octamethyl-28-oxo-3,6,9,12,15,18,21,24-octaoxa-27-azahentetracont-1-yl) ester, disodium salt (9CI) (CA INDEX NAME)


PAGE 1-A




8 (D1-Me)

●2 Na

PAGE 1-B



PAGE 1-C



RN 442155-99-9 CAPLUS

CN Butanedioic acid, sulfo-, 4-(decamethyl-34-oxo-3,6,9,12,15,18,21,24,27,30-decaoxa-33-azaheptatetracont-1-yl) ester, disodium salt (9CI) (CA INDEX NAME)

$\bullet_2 \text{Na}$

AB A high-affinity compound was constructed by linking two relatively weakly interacting monophosphorylated peptides by an oligoethylene glycol spacer. To prepare the required spacers, hexa- and tetraethylene glycol were converted into amino acid superstructures. Benztotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate, N,N-diisopropylethylamine, and 9-fluorenylmethyloxycarbonyl amino acids were used for the couplings. The tandem Src homol.-2 (SH2) domain of murine Syk was cloned, expressed, and purified to determine the affinity of the phosphopeptides and the phosphopeptide hybrids for the Syk tandem SH2 domain. In the surface plasmon resonance (SPR) assay, the peptide

featuring the immunoreceptor tyrosine-based activation motif sequence was extended with an N-terminal 6-aminohexanoic acid moiety to provide a spacer between the SPR sensor chip and the peptide. The mol. construct with the hexaethylene glycol spacer showed an affinity comparable to the native diphosphorylated ITAM peptide. The results indicated that a nonpeptide spacer can substitute the intervening amino acids in the native Syk tandem SH2 domain binding ligand.

IT 437655-98-6P 437655-99-7P

RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(diphosphopeptide analog; oligoethylene glycol derivative spacer preparation and


use in linking monophosphorylated peptides in relation to Syk kinase SH2 domain binding)

RN 437655-98-6 CAPLUS


CN L-Leucinamide, N-acetyl-O-phosphono-L-tyrosyl-L-threonylglycyl-L-leucyl-20-amino-3,6,9,12,15,18-hexaoxaicosanoyl-O-phosphono-L-tyrosyl-L- α -glutamyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B





PAGE 1-C



RN 437655-99-7 CAPLUS
CN L-Leucinamide, N-acetyl-O-phosphono-L-tyrosyl-L-threonylglycyl-L-leucyl-14-amino-3,6,9,12-tetraoxatetradecanoyl-O-phosphono-L-tyrosyl-L- α -glutamyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 391684-35-8P 437655-94-2P 437655-95-3P


437655-96-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; oligoethylene glycol derivative spacer preparation and use in linking monophosphorylated peptides in relation to Syk kinase SH2 domain binding)

RN 391684-35-8 CAPLUS

CN 5,8,11,14,17,20-Hexaoxa-2-azadocosanedioic acid,
1,22-bis(1,1-dimethylethyl) ester (CA INDEX NAME)




PAGE 1-B




RN 437655-94-2 CAPLUS
CN 5,8,11,14-Tetraoxa-2-azahexadecanedioic acid, 1,16-bis(1,1-dimethylethyl)
ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 437655-95-3 CAPLUS
CN 5,8,11,14-Tetraoxa-2-azahexadecanedioic acid, 1-(9H-fluoren-9-ylmethyl)
ester (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



RN 437655-96-4 CAPLUS
CN 5,8,11,14,17,20-Hexaoxa-2-azadocosanedioic acid, 1-(9H-fluoren-9-ylmethyl)
ester (CA INDEX NAME)

PAGE 1-A





OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)

L5 ANSWER 8 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:463245 CAPLUS

DOCUMENT NUMBER: 135:47462

TITLE: Fluorine-containing block copolymers with improved solvent and cold resistance, and their manufacture

INVENTOR(S): Hisamatsu, Yasuyoshi; Tatsu, Harumi

PATENT ASSIGNEE(S): Nippon Mectron Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001172343	A	20010626	JP 1999-362570	19991221
PRIORITY APPLN. INFO.:			JP 1999-362570	19991221

AB The copolymers are manufactured from (a) vinylidene fluoride, (b) other monomers, and (c) $\text{CH}_2\text{:CHCH}_2\text{NHCOCF}(\text{CF}_3)\text{O}[\text{CF}_2\text{CF}(\text{CF}_3)\text{O}]_m\text{Rf}[\text{OCF}(\text{CF}_3)\text{CF}_2]_n\text{OCF}(\text{CF}_3)\text{CONHCH}_2\text{CH:CH}_2$ (I; Rf = C2-6 perfluoroalkylene; m, n > 0; m + n \geq 20). Thus, vinylidene fluoride, perfluoro(Me vinyl ether), and I (Rf = CF_2CF_2 , m + n = 32) were polymerized to give block copolymer. A composition

containing the copolymer was vulcanized to give a test piece showing 23.4% volume change after soaking in MeOH at 40° for 70 h and good low-temperature resistance in T-R test.

IT 344920-39-4P

RL: IMF (Industrial manufacture); PRP (Properties); PREP (Preparation)

(rubber; manufacture of F-containing block copolymers with improved solvent

and

cold resistance)

RN 344920-39-4 CAPLUS



CN Poly[oxy(trifluoro(trifluoromethyl)-1,2-ethanediyl)], α,α' -(1,1,2,2-tetrafluoro-1,2-ethanediyl)bis[ω -[1,2,2,2-tetrafluoro-1-[(2-propenylamino)carbonyl]ethoxy]-, polymer with 1,1-difluoroethene and trifluoro(trifluoromethoxy)ethene, block (9CI) (CA INDEX NAME)

CM 1

CRN 162442-49-1

CMF (C3 F6 O)n (C3 F6 O)n C14 H12 F12 N2 O4


CCI IDS, PMS



CM 2

CRN 1187-93-5


CMF C3 F6 O



CM 3

CRN 75-38-7

CMF C2 H2 F2



L5 ANSWER 9 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:417889 CAPLUS

DOCUMENT NUMBER: 135:262107

TITLE: Evaluation of carboxymethyl pullulan as a novel carrier for targeting immune tissues

AUTHOR(S): Masuda, Kazuyoshi; Sakagami, Masahiro; Horie, Kazutoshi; Nogusa, Hideo; Hamana, Hiroshi; Hirano, Koichiro

CORPORATE SOURCE: Shionogi Research Laboratories, Shionogi and Co., Ltd., Osaka, 553-0002, Japan

SOURCE: Pharmaceutical Research (2001), 18(2), 217-223

CODEN: PHREEB; ISSN: 0724-8741

PUBLISHER: Kluwer Academic/Plenum Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The potential of carboxymethyl pullulan (CMPul) as a carrier for targeting immune tissues was demonstrated, and it was determined whether immune tissues

could be set as the target of an immunosuppressant to treat autoimmune diseases. The biodistribution of CMPul was investigated to evaluate its potency as a carrier for targeting immune tissues. Furthermore, an immunosuppressant-CMPul conjugate was prepared and its suppressive effect on rat adjuvant arthritis was examined. The disappearance rate of 3H-labeled CMPul from the blood circulation was much slower than that of 3H-labeled pullulan (Pul) after i.v. injection to normal rats. The concentration of 3H-labeled CMPul in the spleen and lymph nodes was much higher than that of 3H-labeled Pul at 24 h after the injection, whereas the concentration of 3H-labeled CMPul in the liver was significantly lower than that of 3H-labeled Pul. A similar targeting property of 3H-labeled CMPul for these immune tissues was observed in arthritic rats. A conjugate composed of a novel immunosuppressant PA-48153C and CMPul showed a suppressive effect on rat adjuvacarboxymethylpullulannt arthritis judging from a reduction of the arthritic index and spleen weight and an increase of body weight. CMPul is expected to be a promising carrier for targeting immune tissues with an immunosuppressant to enable treatment of autoimmune diseases.


IT 217180-85-3DP, conjugate with carboxymethylpullulan
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (evaluation of carboxymethyl pullulan as novel carrier for targeting immune tissues)

RN 217180-85-3 CAPLUS


CN 3,6,9,12,15-Pentaoxaheptadecanoic acid, 17-amino-,
 (1R,2S,3R,4S,6E)-1-[[(2R,3R)-3-ethyl-3,6-dihydro-6-oxo-2H-pyran-2-yl]methyl]-3-methoxy-2,4-dimethyl-6-octen-1-yl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



IT 217180-86-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (evaluation of carboxymethyl pullulan as novel carrier for targeting immune tissues)

RN 217180-86-4 CAPLUS

CN 3,6,9,12,15-Pentaoxaheptadecanoic acid, 17-amino-,
 (1R,2S,3R,4S,6E)-1-[[(2R,3R)-3-ethyl-3,6-dihydro-6-oxo-2H-pyran-2-yl]methyl]-3-methoxy-2,4-dimethyl-6-octenyl ester, trifluoroacetate (9CI)

(CA INDEX NAME)


CM 1

CRN 217180-85-3


CMF C31 H55 N O10

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1


CMF C2 H F3 O2




OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:391002 CAPLUS
DOCUMENT NUMBER: 135:153204
TITLE: Synthesis of a Series of Oligo(ethylene glycol)-Terminated Alkanethiol Amides Designed to Address Structure and Stability of Biosensing Interfaces
AUTHOR(S): Svedhem, Sofia; Hollander, Carl-Aake; Shi, Jing; Konradsson, Peter; Liedberg, Bo; Svensson, Stefan C. T.
CORPORATE SOURCE: Divisions of Chemistry and Applied Physics Department

PAGE 1-A




PAGE 1-B




RN 352439-48-6 CAPLUS

CN Acetic acid, 2-[(34-mercapto-19-oxo-3,6,9,12,15-pentaoxa-18-azatetratriacont-1-yl)oxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 352439-49-7 CAPLUS

CN 3,6,9,12,15,18-Hexaoxa-21-azaheptatriacontanamide,
N-hexadecyl-37-mercapto-22-oxo- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 70 THERE ARE 70 CAPLUS RECORDS THAT CITE THIS
RECORD (71 CITINGS)

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:214540 CAPLUS

DOCUMENT NUMBER: 135:30391

TITLE: Synthesis of [Ru(phen)2dppz]2+-tethered oligo-DNA and studies on the metallointercalation mode into the DNA duplex

AUTHOR(S): Ossipov, Dimitri; Pradeepkumar, P. I.; Holmer, Melcer; Chattopadhyaya, Jyoti

CORPORATE SOURCE: Department of Bioorganic Chemistry Biomedical Center, University of Uppsala, Uppsala, Swed.

SOURCE: Journal of the American Chemical Society (2001), 123(15), 3551-3562
CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:30391



AB To explore the binding properties of [Ru(phen)2dppz]2+ complex (phen = 1,10-phenanthroline, dppz = dipyrido[3,2-a:2',3'-c]phenazine) in a sequence-specific manner in DNA duplex, it was tethered through the dppz ligand to a central position as well as both at the 3'- and 5'-ends of oligodeoxyribonucleotide (ODN). The middle [Ru(phen)2dppz]2+-ODN tethered was resolved and isolated as four pure diastereomers, while the 3'- or 5'-[Ru(phen)2dppz]2+-ODNs were inseparable on RP-HPLC. Thermal stability of the (Ru2+-ODN)·DNA duplexes is found to increase considerably ($\Delta T_m = 12.8$ -23.4°), depending upon the site of the covalent attachment of the tethered [Ru(phen)2dppz]2+ complex, or the chirality of the [Ru(phen)2dppz]2+-linker tethered at the middle of the ODN, compared to the unlabeled counterpart. Gross differences in CD between the [Ru(phen)2dppz]2+-tethered and the native DNA duplexes showed that the global duplex conformation of the former has considerably altered from the B-type, but is still recognized by DNase I. The thermal melting studies, CD measurements, as well as DNase I digestion data, are interpreted as a result of intercalation of the dppz moiety, which is realized by threading of the Ru(phen)2 complex part through the DNA duplex core. DNase I footprinting with four diastereomerically pure middle ([Ru(phen)2dppz]2+-ODN)·DNA duplexes furthermore showed that the tethered [Ru(phen)2dppz]2+-linker chirality dictates the stereochem. accessibility of various phosphodiester moieties (around the intercalation site) toward the cleavage reaction by the enzyme. The diastereomerically pure ruthenium-modified duplexes, with the well-defined π -stack, will be useful to explore stereochem.-dependent energy- and electron-transfer chemical to understand oxidative damage to the DNA double helix as well as the long-range energy- and electron-transfer processes with DNA as a reactant.

IT 342906-45-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of [Ru(phen)2dppz]2+-tethered oligodeoxyribonucleotides)

RN 342906-45-0 CAPLUS

CN Ruthenium(1+), [mono[1-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-13-(dipyrido[3,2-a:2',3'-c]phenazin-11-yl- κ N4, κ N5)-13-oxo-3,6,9-trioxo-12-azatridec-1-yl] butanedioato]bis(1,10-phenanthroline- κ N1, κ N10)-, (OC-6-33)-(9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 30 THERE ARE 30 CAPLUS RECORDS THAT CITE THIS
RECORD (30 CITINGS)
REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:183393 CAPLUS

DOCUMENT NUMBER: 134:362955

TITLE: Selective adhesion of endothelial cells to artificial
membranes with a synthetic RGD-lipopeptide

AUTHOR(S): Marchi-Artzner, Valerie; Lorz, Barbara; Hellerer,
Ulrike; Kantlehner, Martin; Kessler, Horst; Sackmann,
Erich

CORPORATE SOURCE: Institut fur Physik, Biophysik E22 Technische
Universitat Munchen, Garching, 85747, Germany

SOURCE: Chemistry--A European Journal (2001), 7(5), 1095-1101
CODEN: CEUJED; ISSN: 0947-6539

PUBLISHER: Wiley-VCH Verlag GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A constrained cyclic Arg-Gly-Asp-D-Phe-Lys, abbreviated as cyclo(-RGDfK-),
lipopeptide has been synthesized and incorporated into artificial
membranes such as giant vesicles with DOPC and solid-supported lipid
bilayers. The selective adhesion and spreading of endothelial cells of
the human umbilical cord on solids functionalized by membranes with this
RGD-lipopeptide have been observed Furthermore, we have demonstrated strong
selective adhesion of giant vesicles to endothelial cells through local
adhesion domains by combined application of hydrodynamic flow field and
reflection interference contrast microscopy (RICM). The adhesion can be

IT 339547-58-9P

RN 339547-58-9 CAPLUS


Absolute stereochemistry.

[illegible]


The chemical structure represents a cyclic peptide derivative. It features a 14-membered ring with two thioether linkages (S). The ring is substituted with a side chain containing a phenyl group (Ph) and a carboxylic acid group (CO₂H). The structure is shown with stereochemistry and labels for various groups: H₂N, NH, (CH₂)₃, (CH₂)₄, R, and Ph.

(selective adhesion of endothelial cells to artificial membranes with a synthetic RGD-lipopeptide)

Absolute stereochemistry.



t-BuO—



RN 339547-56-7 CAPLUS

CN Cyclo[L- α -aspartyl-D-phenylalanyl-N6-(18-octadecyl-1,17-dioxo-3,6,9,12,15-pentaoxa-18-azahexatriacont-1-yl)-L-lysyl-N5-[[[(2,3-dihydro-2,2,4,5,7-pentamethyl-6-benzofuranyl)sulfonyl]amino]iminomethyl]-L-ornithyl], 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
OS.CITING REF COUNT:      30      THERE ARE 30 CAPLUS RECORDS THAT CITE THIS
                                RECORD (30 CITINGS)
REFERENCE COUNT:          38      THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

L5 ANSWER 13 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:52907 CAPLUS
DOCUMENT NUMBER: 134:277052
TITLE: Cell-surface recognition of biotinylated membrane
proteins requires very long spacer arms: an example
from glucose-transporter probes
AUTHOR(S): Hashimoto, Makoto; Yang, Jing; Holman, Geoffrey D.
CORPORATE SOURCE: Department of Biology and Biochemistry, University of
Bath, Bath, BA2 7AY, UK
SOURCE: ChemBioChem (2001), 2(1), 52-59
Published in: Angew. Chem., Int. Ed., 40(1)
CODEN: CBCHFX; ISSN: 1439-4227
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal

LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:277052

AB Glucose transporters (GLUTs) can be photoaffinity labeled by (diazirinetrifluoroethyl)benzoyl-substituted glucose derivs. and the adduct can be recognized, after detergent solubilization of membranes, by using streptavidin-based detection systems. However, in intact cells recognition of photolabeled GLUTs by avidin and anti-biotin antibodies only occurs if the bridge between the photoreactive and the biotin moieties has a min. of 60-70 spacer atoms. We show that a suitably long bridge can be synthesized with a combination of polyethylene glycol and tartrate groups and that introduction of these spacers generates hydrophilic products that can be cleaved with periodate. Introduction of the very long spacers does not appreciably reduce the affinity of interaction of the probes with the transport system.



IT 332941-37-4P 332941-54-5P 332941-56-7P
RL: PNU (Preparation, unclassified); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(reagents with long spacer arms between biotin and photoaffinity label can be used for cell-surface recognition of biotinylated glucose transporters)

RN 332941-37-4 CAPLUS


CN D-Glucose, 4-O-[24-carboxy-2-[[4-[3-(trifluoromethyl)-3H-diazirin-3-yl]benzoyl]amino]-4,7,10,13,16,19,22-heptaooxatetracos-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 332941-54-5 CAPLUS

CN D-Glucose, 4-O-[62-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-25,51,58-trioxo-2-[[4-[3-(trifluoromethyl)-3H-diazirin-3-


yl]benzoyl]amino]-4,7,10,13,16,19,22,29,32,35,38,41,44,47-tetradeca-
 26,50,57-triazadohexacont-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 1-C









RN 332941-56-7 CAPLUS

CN D-Glucose, 4-O-[(31R,32R)-63-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-31,32-dihydroxy-25,30,33,59-tetraoxo-2-[[4-[3-(trifluoromethyl)-3H-diazirin-3-yl]benzoyl]amino]-4,7,10,13,16,19,22,37,40,43,46,49,52,55-tetradeca-26,29,34,58-tetraazatrihexacont-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.





IT 332941-34-1P 332941-35-2P



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(reagents with long spacer arms between biotin and photoaffinity label can be used for cell-surface recognition of biotinylated glucose transporters)

RN 332941-34-1 CAPLUS

CN D-Glucose, 4-O-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-27,27-dimethyl-25-oxo-4,7,10,13,16,19,22,26-octaaoctacos-1-yl]-2,3:5,6-bis-O-(1-methylethylidene)-, 1-(dimethyl acetal) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 332941-35-2 CAPLUS


CN D-Glucose, 4-O-[24-carboxy-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4,7,10,13,16,19,22-heptaotetracos-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 32 THERE ARE 32 CAPLUS RECORDS THAT CITE THIS
RECORD (32 CITINGS)
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:659767 CAPLUS
DOCUMENT NUMBER: 133:242720
TITLE: Bioabsorbable triglycolic acid poly(ester-amide)s for
sutures and implants
INVENTOR(S): Barrows, Thomas Harry
PATENT ASSIGNEE(S): BioAmide, Inc., USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6120788	A	20000919	US 1998-174136	19981016
US 6365172	B1	20020402	US 2000-630118	20000801
PRIORITY APPLN. INFO.:			US 1997-62064P	P 19971016
			US 1998-174136	A3 19981016

AB This invention relates to fiber-forming bioabsorbable poly(ester-amide)s made by the polymerization of diamidediols with 3,6-dioxaoctanedioic acid, also known as "triglycolic acid". More specifically it relates to diol terminated poly(ester-amide)s of triglycolic acid that are optionally further reacted with glycolide, lactide, trimethylene carbonate, epsilon-caprolactone, or p-dioxanone, or mixts. of said cyclic monomers to produce the corresponding block copolymers. Said polymers are useful in the production of surgical sutures having superior performance characteristics including low bending stiffness and in the production of other fiber-based bioabsorbable implants and molded devices.


IT 294198-19-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(bioabsorbable triglycolic acid poly(ester-amide)s for sutures and implants)
RN 294198-19-9 CAPLUS

CN Poly[oxy(1-oxo-1,2-ethanediyl)oxy-1,2-ethanediyl]oxy(2-oxo-1,2-ethanediyl)oxy(2-oxo-1,2-ethanediyl)imino-1,6-hexanediylimino(1-oxo-1,2-ethanediyl)] (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




IT 294198-16-6DP, 1,6-hexanediol terminated 294198-17-7P
 294198-18-8P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (bioabsorbable triglycolic acid poly(ester-amide)s for sutures and implants)
 RN 294198-16-6 CAPLUS
 CN Poly[oxy(1-oxo-1,2-ethanediyl)oxy-1,2-ethanediyl]oxy(2-oxo-1,2-ethanediyl)oxy(2-oxo-1,2-ethanediyl)imino-1,6-hexanediylimino(1-oxo-1,2-ethanediyl)], α -(6-hydroxyhexyl)- ω -[(6-hydroxyhexyl)oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 294198-17-7 CAPLUS
 CN 1,4-Dioxane-2,5-dione, polymer with
 α -(6-hydroxyhexyl)- ω -[(6-hydroxyhexyl)oxy]poly[oxy(1-oxo-1,2-ethanediyl)oxy-1,2-ethanediyl]oxy(2-oxo-1,2-ethanediyl)oxy(2-oxo-1,2-ethanediyl)imino-1,6-hexanediylimino(1-oxo-1,2-ethanediyl)], block (9CI) (CA INDEX NAME)


CM 1

CRN 294198-16-6
 CMF (C16 H26 N2 O8)_n C12 H26 O3
 CCI PMS

PAGE 1-A




PAGE 1-B



CM 2

CRN 502-97-6

CMF C4 H4 O4



RN 294198-18-8 CAPLUS

CN 1,4-Dioxane-2,5-dione, 3,6-dimethyl-, polymer with
 α -(6-hydroxyhexyl)- ω -[(6-hydroxyhexyl)oxy]poly[oxy(1-oxo-1,2-ethanediyl)oxy-1,2-ethanediyl]oxy(2-oxo-1,2-ethanediyl)oxy(2-oxo-1,2-ethanediyl)imino-1,6-hexanediylimino(1-oxo-1,2-ethanediyl)], block (9CI)
 (CA INDEX NAME)


CM 1

CRN 294198-16-6


CMF (C16 H26 N2 O8)_n C12 H26 O3

CCI PMS

PAGE 1-A




PAGE 1-B



CM 2

CRN 95-96-5

CMF C6 H8 O4



OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (27 CITINGS)
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:500228 CAPLUS

DOCUMENT NUMBER: 133:262810

TITLE: Preparation of Mixed Self-Assembled Monolayers (SAMs) That Resist Adsorption of Proteins Using the Reaction of Amines with a SAM That Presents Interchain Carboxylic Anhydride Groups

AUTHOR(S): Chapman, Robert G.; Ostuni, Emanuele; Yan, Lin; Whitesides, George M.

CORPORATE SOURCE: Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, 02138, USA

SOURCE: Langmuir (2000), 16(17), 6927-6936

CODEN: LANGD5; ISSN: 0743-7463

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 133:262810


AB This paper describes a procedure for preparing mixed self-assembled monolayers (mixed SAMs) on gold that resist the nonspecific adsorption of proteins from solution. This method was tested using α -amino derivs. of ω -hydroxy- and ω -methoxy-oligo(ethylene glycols): $\text{H}_2\text{N}(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_3$ and $\text{H}_2\text{N}(\text{CH}_2\text{CH}_2\text{O})_n\text{H}$ ($n = 3, 6$). Mixed SAMs were prepared by allowing these amines to react with a SAM presenting interchain carboxylic anhydride groups. The resistance of the resulting surfaces to adsorption of several proteins-carbonic anhydrase (EC 4.2.1.1), RNase A (EC 3.1.27.5), lysozyme (EC 3.2.1.17), and fibrinogen-was examined using surface plasmon resonance (SPR) spectroscopy. These mixed SAMs resist the nonspecific adsorption of proteins approx. as effectively as single-component SAMs prepared using the conventional method involving chemisorption of oligo(ethylene glycol)-terminated alkanethiols on gold. Characterization of the mixed SAM that presents a 1:1 mixture of $-\text{OCNH}(\text{CH}_2\text{CH}_2\text{O})_6\text{CH}_3$ and $\text{CO}_2\text{H}/\text{CO}_2-$ groups by polarized IR external reflectance spectroscopy indicates that the ethylene glycol units are in an amorphous conformation. A model surface for use in studies of biospecific adsorption was synthesized by reacting the anhydride groups with a mixture of $\text{H}_2\text{N}(\text{CH}_2\text{CH}_2\text{O})_6\text{H}$ and $\text{H}_2\text{N}(\text{CH}_2\text{CH}_2\text{O})_6\text{CH}_2\text{CONH}(\text{CH}_2)_6\text{NHCOC}_6\text{H}_4\text{SO}_2\text{NH}_2$; the resulting system was examined for its ability to bind bovine carbonic anhydrase by SPR. The values of the relevant consts. were $k_{\text{off}} = 0.0054 \text{ s}^{-1}$, $k_{\text{on}} = 13\,000 \text{ M}^{-1} \text{ s}^{-1}$, and $K_d = 0.42 \mu\text{M}$. These values agree with values obtained by other means. The reaction of amines with SAMs that present interchain carboxylic anhydrides provides an exptl. simple route to the formation of mixed SAMs that resist the nonspecific adsorption of proteins or that adsorb a protein of interest biospecifically.

IT 297162-50-6P 297162-51-7P 297162-52-8P
 297162-53-9P 297162-54-0P 297162-55-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

RN 297162-50-6 CAPLUS


PAGE 1-A




PAGE 1-A





PAGE 1-A








RN 297162-53-9 CAPLUS
 CN 5,8,11,14,17,20-Hexaoxa-2,23,30-triazahentriacontanedioic acid, 22-oxo-,
 31-(1,1-dimethylethyl) 1-(phenylmethyl) ester (CA INDEX NAME)




RN 297162-54-0 CAPLUS
 CN 5,8,11,14,17,20-Hexaoxa-2,23-diazanonacosanoic acid, 29-amino-22-oxo-,
 phenylmethyl ester (CA INDEX NAME)





RN 297162-55-1 CAPLUS
 CN 5,8,11,14,17,20-Hexaoxa-2,23,30-triazahentriacontanoic acid,
 31-[4-(aminosulfonyl)phenyl]-22,31-dioxo-, phenylmethyl ester (CA INDEX
 NAME)





RN 297162-57-3 CAPLUS
 CN 3,6,9,12,15,18-Hexaoxaeicosanamide,
 20-amino-N-[6-[[4-(aminosulfonyl)benzoyl]amino]hexyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 125 THERE ARE 125 CAPLUS RECORDS THAT CITE THIS
 RECORD (126 CITINGS)
 REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:41754 CAPLUS

DOCUMENT NUMBER: 132:208087

TITLE: Dipyrido[3,2-a:2',3'-c]phenazine-tethered oligo-DNA:
 synthesis and thermal stability of their DNA ·
 DNA and DNA · RNA duplexes and DNA · DNA
 · DNA triplexes

AUTHOR(S): Ossipov, Dimitri; Zamaratski, Edouard; Chattopadhyaya,
 Jyoti

CORPORATE SOURCE: Department of Bioorganic Chemistry, Biomedical Center,
 University of Uppsala, Swed.

SOURCE: Helvetica Chimica Acta (1999), 82(12), 2186-2200
 CODEN: HCACAV; ISSN: 0018-019X

PUBLISHER: Verlag Helvetica Chimica Acta

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Dipyrido[3,2-a:2',3'-c]phenazine (dppz) derivs. were conjugated to 9-mer
 and 18-mer DNA (ODN) at a site without nucleobase, either at the 5'- or
 3'-end or at an internucleotide position, via linkers of 7, 12, or 18 atoms
 lengths. These dppz-linked ODNs were synthesized using novel backbone
 glycerol phosphoramidites: glycerol, serving as artificial nucleoside
 without nucleobase, was modified to amines which were suitable for the
 subsequent key reaction with dppz-carboxylic acid. The products of these
 reactions were then transformed to the standard phosphoramidite derivs. or
 used for loading on a CPG support. The dppz-modified ODNs were


IT 259796-43-5DP, CPG bound 259796-44-6DP, CPG bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

RN 259796-43-5 CAPLUS

PAGE 1-A




PAGE 1-B




CN Butanedioic acid, 1-[1-[[bis(4-methoxyphenyl)phenylmethoxy)methyl]-19-oxo-19-quinoxalino[2,3-f][1,10]phenanthrolin-11-yl]-3,6,9,12,15-pentaoxa-18-azanonadec-1-yl] ester (CA INDEX NAME)

PAGE 1-A





PAGE 1-B





IT 259796-43-5P 259796-44-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis and thermal stability of dipyrdo[phenazine]-tethered
 oligo-DNA and their DNA/RNA duplexes and triplexes)
 RN 259796-43-5 CAPLUS
 CN Butanedioic acid, 1-[1-[[bis(4-methoxyphenyl)phenylmethoxy)methyl]-13-oxo-
 13-quinoxalino[2,3-f][1,10]phenanthroline-11-yl]-3,6,9-trioxa-12-azatridec-1-
 yl] ester (CA INDEX NAME)

PAGE 1-A





RN 259796-44-6 CAPLUS
 CN Butanedioic acid, 1-[1-[[bis(4-methoxyphenyl)phenylmethoxy)methyl]-19-oxo-19-quinoxalino[2,3-f][1,10]phenanthroline-11-yl]-3,6,9,12,15-pentaoxa-18-azanonadec-1-yl] ester (CA INDEX NAME)



OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)
 REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1999:796151 CAPLUS
 DOCUMENT NUMBER: 132:36866
 TITLE: Manufacture of fluoro-containing block copolymers
 INVENTOR(S): Tatsu, Haruyoshi; Hisamatsu, Yasuyoshi
 PATENT ASSIGNEE(S): Nippon Mektron, Japan
 SOURCE: Ger. Offen., 10 pp.
 CODEN: GWXXBX

DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19926260	A1	19991216	DE 1999-19926260	19990609
JP 11349647	A	19991221	JP 1998-163091	19980611
JP 3336958	B2	20021021		
US 6160051	A	20001212	US 1999-315771	19990520

PRIORITY APPLN. INFO.: JP 1998-163091 A 19980611

AB The title copolymers are manufactured by copolymerizing CH₂:CHF and ≥1 other fluoro monomer in the presence of iodo-terminated poly(perfluoromethyloxiranes) IZpCF(CF₃)O[CF₂CF(CF₃)O]_mZ₁[OCF(CF₃)CF₂]nOCF(CF₃)ZpI [I; Z = C₂-8 (O-interrupted) (polyfluoro)alkylene, alkyleneamide, phenylenediamide; Z₁ = C₂-6 perfluoroalkylene; m, n = pos. whole number; m + n = >20; p = 0, 1]. For example, a mixture of diglyme 300, CsCO₃ 150 and iodine 160 g was stirred for 4 h at 35-50°, 3352 g of a com. dicarboxylic acid difluoride FOCCF(CF₃)O[CF₂CF(CF₃)O]_mCF₂CF₂[OCF(CF₃)CF₂]nOCF(CF₃)COF (m + n = 51) was added and the stirring continued (gas evolution). When effervescence ceased the reaction mixture was worked up to give I (Z₁ = CF₂CF₂, p = 0) (II) having mol. wt 9050. A mixture of CF₂:CF₂ 183, CH₂:CHF 821, CF₂:CFOCF₃ 608, CF₂:CFOCF₂CF₂Br 12.1, II 416.4, Na₂HPO₄ 11.0, NaHSO₃ 0.8, C₃F₇O(CF₂)₃OCF(CF₃)CO₂NH₄ 15.4 and (CF₃)₂CHOH 66 g in 3660 mL H₂O was warmed up to 45°, 1.6 g K₂S₂O₈ was added and the polymerization continued for 24 h to give 2010 g copolymer having Mooney viscosity ML1+10 23 (125°), which was used to produce crosslinked fluoro rubber.

IT 252680-99-2P
 RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (crosslinked, rubber; manufacture of fluoro rubber containing copolymers of fluoro monomers and iodo-terminated poly(perfluoromethyloxiranes))

RN 252680-99-2 CAPLUS

CN Poly[oxy(trifluoro(trifluoromethyl)-1,2-ethanediyl)],
 α, α' -(1,1,2,2-tetrafluoro-1,2-ethanediyl)bis[ω -[1-[[[4-[(difluoroiodoacetyl)amino]phenyl]amino]carbonyl]-1,2,2,2-tetrafluoroethoxy]-, polymer with (2-bromo-1,1,2,2-tetrafluoroethoxy)trifluoroethene, 1,1-difluoroethene, tetrafluoroethene and trifluoro(trifluoromethoxy)ethene (9CI) (CA INDEX NAME)


CM 1


CRN 252680-36-7

CMF (C₃ F₆ O)_n (C₃ F₆ O)_n C₂₄ H₁₂ F₁₆ I₂ N₄ O₆

CCI IDS, PMS

PAGE 1-A






CM 2

CRN 85737-06-0


CMF C4 Br F7 O



CM 3

CRN 1187-93-5


CMF C3 F6 O



CM 4

CRN 116-14-3


CMF C2 F4



CM 5


CRN 75-38-7

CMF C2 H2 F2




IT 252680-36-7P
 RL: IMF (Industrial manufacture); NUU (Other use, unclassified); PREP
 (Preparation); USES (Uses)
 (manufacture of fluoro rubber containing copolymers of fluoro monomers and)
 RN 252680-36-7 CAPLUS
 CN Poly[oxy(trifluoro(trifluoromethyl)-1,2-ethanediyl)],
 α,α' -(1,1,2,2-tetrafluoro-1,2-ethanediyl)bis[ω -[1-[[4-
 [(difluoroiodoacetyl)amino]phenyl]amino]carbonyl]-1,2,2,2-
 tetrafluoroethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (3 CITINGS)

L5 ANSWER 18 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1999:773409 CAPLUS
 DOCUMENT NUMBER: 132:122950
 TITLE: Synthesis of Polyamide Oligomers Based on
 14-Amino-3,6,9,12-tetraoxatetradecanoic Acid
 AUTHOR(S): Dhawan, Rajiv; Kadijk, Mark G. A.; Joikinen, Terry J.;
 Feng, Michael; Ansell, Steven M.
 CORPORATE SOURCE: Inex Pharmaceuticals Corp., Burnaby, BC, V5J 5J8, Can.
 SOURCE: Bioconjugate Chemistry (2000), 11(1), 14-21
 CODEN: BCCHE; ISSN: 1043-1802
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A series of oligomers of polyamides based on
 14-amino-3,6,9,12-tetraoxatetradecanoic acid monomers (ATTAn) was
 synthesized. These materials were designed as monodisperse analogs of
 poly(ethylene glycol) for use in biomedical applications where
 reproducible behavior is important. Synthesis of the monomer was
 evaluated using two routes. For small-scale preps., tetraethylene glycol
 (TEG) was monoprotected with dihydropyran, converted to an alkoxide, and

alkylated with Et bromoacetate. On larger scales, TEG was alkylated directly by treatment with sodium, followed by Et bromoacetate. The amine function was introduced by mesylation followed by treatment with sodium azide. Reduction of the azide to amino groups was performed over Pd/C using either hydrogen or formic acid as proton sources. Assembly of the oligomers was accomplished using standard DCC/NHS chemical and an iterative dimerization sequence after appropriate deprotection of a pair of monomers. The amino group was protected by retaining the azido group as a latent amine. A series of ATTAN oligomers was prepared (n = 1-8). A lipid conjugate of the octamer, ATTA8-DSPE, was synthesized.


IT 229645-50-5P 229645-52-7P 229645-54-9P
 229645-56-1P 256397-66-7P 256397-67-8P
 256397-68-9P 256397-69-0P 256397-70-3P
 256397-71-4P 256397-72-5P 256397-73-6P
 256397-74-7P 256397-75-8P 256397-76-9P
 256397-77-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of polyamide oligomers based on
 14-amino-3,6,9,12-tetraoxatetradecanoic acid)

RN 229645-50-5 CAPLUS


CN 3,6,9,12-Tetraoxatetradecanoic acid, 14-amino-, ethyl ester (CA INDEX NAME)




RN 229645-52-7 CAPLUS

CN 3,6,9,12,18,21,24,27-Octaoxa-15-azanonacosanoic acid, 29-azido-16-oxo-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 229645-54-9 CAPLUS

CN 3,6,9,12,18,21,24,27,33,36,39,42,48,51,54,57-Hexadeca-15,30,45-triazanapentacontanoic acid, 59-azido-16,31,46-trioxo-, ethyl ester (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 1-C



PAGE 1-D




RN 229645-56-1 CAPLUS
CN 3,6,9,12,18,21,24,27,33,36,39,42,48,51,54,57,63,66,69,72,78,81,84,87,93,96,
99,102,108,111,114,117-Dotriacontaoxa-15,30,45,60,75,90,105-
heptaazanonadecahectanoic acid, 119-azido-16,31,46,61,76,91,106-heptaoxo-,
ethyl ester (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 256397-66-7 CAPLUS
CN 3,6,9,12,18,21,24,27,33,36,39,42-Dodecaoxa-15,30-diazatetratetracontanoic
acid, 44-azido-16,31-dioxo-, ethyl ester (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 1-C




RN 256397-67-8 CAPLUS
CN 3,6,9,12,18,21,24,27,33,36,39,42,48,51,54,57,63,66,69,72-Eicosa-
15,30,45,60-tetraazatetraheptacontanoic acid,
74-azido-16,31,46,61-tetraoxo-, ethyl ester (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 1-D




PAGE 1-E




RN 256397-68-9 CAPLUS
CN 3,6,9,12,18,21,24,27,33,36,39,42,48,51,54,57,63,66,69,72,78,81,84,87-
Tetracosaoxa-15,30,45,60,75-pentaazanonaoctacontanoic acid,
89-azido-16,31,46,61,76-pentaoxo-, ethyl ester (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 1-D



PAGE 1-E



RN 256397-69-0 CAPLUS


CN 3,6,9,12,18,21,24,27,33,36,39,42,48,51,54,57,63,66,69,72,78,81,84,87,93,96
,99,102-Octacosaoxa-15,30,45,60,75,90-hexaazatetrahectanoic acid,
104-azido-16,31,46,61,76,91-hexaoxo-, ethyl ester (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 256397-70-3 CAPLUS

CN Acetic acid, 2-[2-[2-[2-[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]ethoxy]-
(CA INDEX NAME)




PAGE 1-A







RN 256397-71-4 CAPLUS

CN Acetic acid, 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]- (CA INDEX NAME)




RN 256397-72-5 CAPLUS


CN Acetic acid, 2-[2-[2-[2-[2-[[2-[2-[2-[2-[2-[[2-[2-[2-[2-[2-[[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]- (CA INDEX NAME)



PAGE 1-C



PAGE 1-D



RN 256397-73-6 CAPLUS


CN Acetic acid, 2-[(116-azido-13,28,43,58,73,88,103-hepta-oxo-3,6,9,15,18,21,24,30,33,36,39,45,48,51,54,60,63,66,69,75,78,81,84,90,93,96,99,105,108,111,114-hentriacontaoxa-12,27,42,57,72,87,102-heptaaza-hexadecahect-1-yl)oxy]- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 256397-74-7 CAPLUS

CN 3,6,9,12,18,21,24,27-Octaoxa-15-azanonacosanoic acid, 29-amino-16-oxo-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 256397-75-8 CAPLUS


CN 3,6,9,12,18,21,24,27,33,36,39,42-Dodecaoxa-15,30-diazatetracontanoic acid, 44-amino-16,31-dioxo-, ethyl ester (CA INDEX NAME)

PAGE 1-A







PAGE 1-B





RN 256397-76-9 CAPLUS
 CN 3,6,9,12,18,21,24,27,33,36,39,42,48,51,54,57-Hexadecaoxa-15,30,45-triazanonapentacontanoic acid, 59-amino-16,31,46-trioxo-, ethyl ester (CA INDEX NAME)



RN 256397-77-0 CAPLUS
 CN 3,6,9,12,18,21,24,27,33,36,39,42,48,51,54,57,63,66,69,72,78,81,84,87,93,96,99,102,108,111,114,117-Dotriacontaoxa-15,30,45,60,75,90,105-heptaazanonadecahectanoic acid, 119-amino-16,31,46,61,76,91,106-heptaoxo-, ethyl ester (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 229645-58-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of polyamide oligomers based on
 14-amino-3,6,9,12-tetraoxatetradecanoic acid)

RN 229645-58-3 CAPLUS

CN Octadecanoic acid, (1R)-1-(126-azido-3-hydroxy-3-oxido-8,23,38,53,68,83,98,113-octaexo-2,4,10,13,16,19,25,28,31,34,40,43,46,49,55,58,61,64,70,73,76,79,85,88,91,94,100,103,106,109,115,118,121,124-tetratriacontaoxa-7,22,3752,67,82,97,112-octaaza-3-phosphahexacosahect-1-yl)-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:722423 CAPLUS

DOCUMENT NUMBER: 132:313453

TITLE: Oligo(14-amino-3,6,9,12-tetraoxatetradecanoic
acid)-lipid conjugates for use as steric barrier
molecules in liposomes

AUTHOR(S): Ansell, S. M.; Kojic, L. D.; Boey, A.; Klimuk, S. K.;
Harasym, T. O.; Semple, S. C.

CORPORATE SOURCE: Inex Pharmaceuticals Corp., Burnaby, V5J 5J8, Can.

SOURCE: Proceedings of the International Symposium on
Controlled Release of Bioactive Materials (1999),
26th, 667-668

CODEN: PCRMEY; ISSN: 1022-0178

PUBLISHER: Controlled Release Society, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Polyamide oligomers (based on 14-amino-3,6,9,12-tetraoxatetradecanoic
acid)-lipid conjugates can be used in most liposome applications where PEG
is currently used. The new lipids were nontoxic, did not induce immune
responses in vivo and did not adversely affect drug formulation. The
oligomers are monodisperse, can be produced in a wide range of specific
sizes and are intrinsically heterobifunctional.

IT 195071-49-9DP, oligomers, conjugates with
distearoylphosphatidylethanolamine 265983-94-6DP, conjugates
with distearoylphosphatidylethanolamine
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(oligo(14-amino-3,6,9,12-tetraoxatetradecanoic acid)-lipid conjugates
for use as steric barrier mols. in liposomes)

RN 195071-49-9 CAPLUS

CN Acetic acid, 2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]- (CA INDEX
NAME)

$\text{H}_2\text{N}-\text{CH}_2-\text{CH}_2-\text{O}-\text{CH}_2-\text{CH}_2-\text{O}-\text{CH}_2-\text{CH}_2-\text{O}-\text{CH}_2-\text{CH}_2-\text{O}-\text{CH}_2-\text{CO}_2\text{H}$

RN 265983-94-6 CAPLUS

CN 3,6,9,12-Tetraoxatetradecanoic acid, 14-amino-, ethyl ester, polymer with
14-azido-3,6,9,12-tetraoxatetradecanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 229645-50-5


CMF C12 H25 N O6

$$\begin{array}{c} \text{O} \\ || \\ \text{EtO}-\text{C}-\text{CH}_2-\text{O}-\text{CH}_2-\text{CH}_2-\text{O}-\text{CH}_2-\text{CH}_2-\text{O}-\text{CH}_2-\text{CH}_2-\text{O}-\text{CH}_2-\text{CH}_2-\text{NH}_2 \end{array}$$


CM 2

CRN 201467-81-4

CMF C10 H19 N3 O6




IT 229645-50-5P 229645-52-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (oligo(14-amino-3,6,9,12-tetraoxatetradecanoic acid)-lipid conjugates
 for use as steric barrier mols. in liposomes)
 RN 229645-50-5 CAPLUS
 CN 3,6,9,12-Tetraoxatetradecanoic acid, 14-amino-, ethyl ester (CA INDEX
 NAME)




RN 229645-52-7 CAPLUS
 CN 3,6,9,12,18,21,24,27-Octaoxa-15-azanonacosanoic acid, 29-azido-16-oxo-,
 ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1999:501607 CAPLUS
 DOCUMENT NUMBER: 132:93184
 TITLE: Study on polyamides. VII. Synthesis of open chain
 ether with pyridine as terminal group
 AUTHOR(S): Jiao, Tian-Quan; Wang, Yan-Bo; Tan, Xiao-Mei; Liu,
 Quan-Zhong
 CORPORATE SOURCE: Department of Chemistry, State Key Laboratory of
 Applied Organic Chemistry, Lanzhou University,
 Lanzhou, 730000, Peop. Rep. China
 SOURCE: Hecheng Huaxue (1999), 7(2), 207-209
 CODEN: HEHUE2; ISSN: 1005-1511
 PUBLISHER: Hecheng Huaxue Bianjibu
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese
 GI




AB Five title compds. I ($n = 0, 1, 2, 4$; $X = O$, electron pairs), II were prepared and characterized by elemental anal., IR, 1H NMR and MS spectroscopy.

IT 254896-77-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of polyamides)


RN 254896-77-0 CAPLUS

CN 3,6,9,12-Tetraoxatetradecanediamide, N1,N14-di-2-pyridinyl- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L5 ANSWER 21 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:334629 CAPLUS

DOCUMENT NUMBER: 131:149166

TITLE: Application of
Oligo-(14-amino-3,6,9,12-tetraoxatetradecanoic acid)
Lipid Conjugates as Steric Barrier Molecules in
Liposomal Formulations

AUTHOR(S): Ansell, Steven M.; Kojic, Ljiljana D.; Hankins, Janet S.; Sekirov, Laura; Boey, Anthony; Lee, Dora K.; Bennett, Athena R.; Klimuk, Sandra K.; Harasym, Troy O.; Santos, Nancy Dos; Semple, Sean C.

CORPORATE SOURCE: Inex Pharmaceuticals Corp., Burnaby, BC, V5J 5J8, Can.
SOURCE: Bioconjugate Chemistry (1999), 10(4), 653-666
CODEN: BCCHE; ISSN: 1043-1802

PUBLISHER: American Chemical Society


DOCUMENT TYPE: Journal

LANGUAGE: English

AB Lipid conjugates of oligo-(14-amino-3,6,9,12-tetraoxatetradecanoic acid) (ATTAn) were synthesized as monodisperse analogs of poly(ethylene glycol) (PEG) derivs. used in liposomal drug delivery systems. The new lipids were shown to be at least equivalent to MePEGA-2000-DSPE in assays designed to evaluate the effectiveness of polymers as steric barrier mols. in liposomes. Liposomes containing 1-5% of ATTA8-DSPE (octamer) showed comparable long circulation behavior relative to PEG-2000-DSPE analogs. Surprisingly, the shorter ATTA4-DSPE (tetramer) appeared to be quite

effective in reducing clearance. Liver enzyme levels and systemic single dose tolerability of ATTA8-DSPE liposomes were comparable to controls, suggesting that the new materials are nontoxic. Prolonged exposure of ATTA8-DSPE liposomes to splenocytes in vitro showed no evidence of mitogenicity relative to controls or MePEG-2000-DSPE liposomes. ATTA8-DSPE was as effective as MePEG-2000-DSPE in preventing complement activation by cationic liposome systems. Repeat dosage in vivo regimes in ICR mice using DSPC/cholesterol liposomes, with and without 5% ATTA8-DSPE and MePEG-2000-DSPE, showed no evidence of enhanced clearance on successive doses. Splenocytes recovered after repeat doses showed no significant evidence of mitogenicity on restimulation with liposomes. Cellular differentiation and activation marker levels in splenocytes recovered after the fourth in vivo administration were at normal levels. These results suggest that ATTA oligomers do not induce an immune response in isolation. It was demonstrated that ATTA8-DSPE could be used to replace PEG-lipids in the formulation of doxorubicin, plasmid DNA and oligonucleotides using a variety of formulation techniques. The study demonstrates that ATTA oligomers can be safely and effectively used in place of poly(ethylene glycol) as well-defined biomaterials in liposomal applications where reproducible behavior is critical

IT 195071-49-9D, oligomers
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (application of 14-amino-3,6,9,12-tetraoxatetradecanoic acid oligomers in lipid conjugates as steric barrier mols. in liposomes)
 RN 195071-49-9 CAPLUS
 CN Acetic acid, 2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]- (CA INDEX NAME)



IT 229645-63-0P 229645-64-1P 229645-65-2P
 229645-74-3P 229645-75-4P 236103-97-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (application of 14-amino-3,6,9,12-tetraoxatetradecanoic acid oligomers in lipid conjugates as steric barrier mols. in liposomes)
 RN 229645-63-0 CAPLUS
 CN 5,8,11,14,20,23,26,29,35,38,41,44,50,53,56,59,65,68,71,74,80,83,86,89,95,98,101,104-Octacosaoxa-2,17,32,47,62,77,92-heptaazahexahectanamide, 1-[[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]methyl]-1,16,31,46,61,76,91-heptaaxo-N,N-ditetradecyl- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 229645-64-1 CAPLUS
 CN 5,8,11,14,20,23,26,29,35,38,41,44,50,53,56,59,65,68,71,74,80,83,86,89,95,98,101,104-Octacosaoxa-2,17,32,47,62,77,92-heptaazahexahectanamide, 1-[[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]methyl]-N,N-dihexadecyl-1,16,31,46,61,76,91-heptaaxo- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 229645-65-2 CAPLUS
 CN Tetradecanoic acid, 1-(131-azido-3,18,33,48,63,78,103,118-octaaxo-5,8,11,14,20,23,26,29,35,38,41,44,50,53,56,59,65,68,71,74,90,93,96,99,105,108,111,114,120,123,126,129-dotriacontaaxo-2,17,32,47,62,77,102,117-octaazahentriacontahect-1-yl)-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 229645-74-3 CAPLUS

CN Hexadecanoic acid, 1-(131-azido-3,18,33,48,63,78,103,118-octaoxo-5,8,11,14,20,23,26,29,35,38,41,44,50,53,56,59,65,68,71,74,90,93,96,99,105,108,111,114,120,123,126,129-dotriacontaoxa-2,17,32,47,62,77,102,117-octaazahentriacontahect-1-yl)-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 229645-75-4 CAPLUS

CN Octadecanoic acid, 1-(131-azido-3,18,33,48,63,78,103,118-octaoxo-5,8,11,14,20,23,26,29,35,38,41,44,50,53,56,59,65,68,71,74,90,93,96,99,105,108,111,114,120,123,126,129-dotriacontaoxa-2,17,32,47,62,77,102,117-octaazahentriacontahect-1-yl)-1,2-ethanediyl ester (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 236103-97-2 CAPLUS


CN Octadecanoic acid, (1R)-1-(65-azido-3-hydroxy-3-oxido-7,22,37,52-tetraoxo-2,4,9,12,15,18,24,27,30,33,39,42,45,48,54,57,60,63-octadeca-6,21,36,51-tetraaza-3-phosphapentahexacont-1-yl)-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 1-C





OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:804207 CAPLUS

DOCUMENT NUMBER: 130:57210

TITLE: Use of drug carriers for producing lymph node migrating drugs

INVENTOR(S): Horie, Kazutoshi; Masuda, Kazuyoshi; Sakagami, Masahiro

PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9855149	A1	19981210	WO 1998-JP2373	19980529
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9874545	A	19981221	AU 1998-74545	19980529
PRIORITY APPLN. INFO.:			JP 1997-145011	A 19970603
			WO 1998-JP2373	W 19980529

AB The invention relates to the use of drug carriers represented by the following general formula for producing lymph node migrating drugs: E-(T1-T2-F)p, wherein E represents a polysaccharide such as CM chitosan, CM pullulan or CM dextran or a deriv. thereof; T1 represents -NH-, -NHCO-, -CONH- or -NHCONH-; T2 represents -CH2CH2(OCH2CH2)m-, -(CH2)n-, etc.; F represents a monosaccharide optionally N- or O-acylated, O-alkylated or esterified, or an oligosaccharide consisting of 2 to 6 mols. of the monosaccharide or is deriv.; and p is an integer of from 0 to 1,000.

IT 217180-84-2P 217180-86-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(use of drug carriers for producing lymph node migrating drugs)


RN 217180-84-2 CAPLUS

CN 5,8,11,14,17-Pentaoxa-2-azanonadecanedioic acid, 1-(1,1-dimethylethyl) 19-[(1R,2S,3R,4S,6E)-1-[(2R,3R)-3-ethyl-3,6-dihydro-6-oxo-2H-pyran-2-yl]methyl]-3-methoxy-2,4-dimethyl-6-octen-1-yl] ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




CM 1

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



CM 2


CRN 76-05-1
CMF C2 H F3 O2




IT 217180-85-3DP, reaction products with carboxymethylpullulan
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(use of drug carriers for producing lymph node migrating drugs)
RN 217180-85-3 CAPLUS
CN 3,6,9,12,15-Pentaoxaheptadecanoic acid, 17-amino-,
(1R,2S,3R,4S,6E)-1-[[(2R,3R)-3-ethyl-3,6-dihydro-6-oxo-2H-pyran-2-yl]methyl]-3-methoxy-2,4-dimethyl-6-octen-1-yl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:682650 CAPLUS
DOCUMENT NUMBER: 130:62859
TITLE: Inhibiting the dimerization of HIV-1 protease
AUTHOR(S): Zutshi, Reena; Shultz, Michael D.; Ulysse, Luckner; Lutgring, Ray; Bishop, Patricia; Schweitzer, Barbara; Vogel, Karen; Franciskovich, Jeff; Wilson, Matt; Chmielewski, Jean
CORPORATE SOURCE: Department Chemistry, Purdue University, West

SOURCE: Lafayette, IN, 47907, USA
 Synlett (1998), (10), 1040-1044
 CODEN: SYNLES; ISSN: 0936-5214
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Disrupting protein-protein interactions in multi-subunit enzymes is currently an under-utilized mode of inhibition, and little information exists to assist the researcher in the design of agents to effect such a change within the enzyme. These limitations were addressed by providing a general strategy for the design of dimerization inhibitors of the therapeutically significant enzyme HIV-1 protease. A successful approach to the design of dimerization inhibitors of HIV-1 protease was demonstrated. Using peptides of the dimerization interface as a starting point for inhibitor design, the authors found that the activities of the interfacial peptides were enhanced through crosslinking, and that the nature of the crosslinking was essential for high efficacy. We found for this class of inhibitors the terminal, aromatic residues were essential components for inhibition, and that modifications of these residues based on an anal. of their binding site in an HIV-1 protease monomer could lead to further enhancements in efficacy.

IT 217810-42-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation of dimerization inhibitors for HIV-1 proteinase)

RN 217810-42-9 CAPLUS


CN L-Tryptophan, 1-(13-carboxy-1-oxo-3,6,9,12-tetraoxatridec-1-yl)-L-prolyl-L-glutaminyl-L-isoleucyl-L-threonyl-L-leucyl-, (1→1')-amide with L-seryl-L-threonyl-L-leucyl-L-asparaginyl-L-phenylalanine (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:585745 CAPLUS

DOCUMENT NUMBER: 129:277693

ORIGINAL REFERENCE NO.: 129:56591a, 56594a

TITLE: Bleach activators and bleach compositions containing the same, showing high bleaching powder for both hydrophilic and hydrophobic soils without discoloring the substrate

INVENTOR(S): Yokoi, Kenji; Nakagawa, Ryuichi

PATENT ASSIGNEE(S): Lion Corp., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10237497	A	19980908	JP 1997-39051	19970224
PRIORITY APPLN. INFO.:			JP 1997-39051	19970224


AB The title bleach activators contain ≥ 1 R2[N(COR1)Q]2 (I), R2(CONR4Q)2, R2[OCH2CH(R6)OQ]2, and R2[OCH2CH(CH2OR8)OQ]2, wherein Q = (C2H4O)l(AO)mCH(R3)(CH2)nCOL, R1 = C1-21 alkyl, alkenyl, phenyl; R2 = C1-10 alkylene; R3 = H, C1-10 alkyl, alkenyl, hydroxyalkyl; R4, R6, R8 = C1-22 alkyl, alkenyl, phenyl; A = C2-4 alkylene; l, m = 0-20; n 0-12; L = H, OC6H4SO3M, OC6H4CO2M, NH(CH2)rCO2C6H4SO3M, NH(CH2)rCO2C6H4CO2M, C3-12 lactonyl, 3-Y-substituted 2,5-dioxotetrahydropyrrolyl, excluding both L being H; r = 1-11; x = 2-11; Y = H, SO3M, CO2M; M = H, alkali metal, alkaline earth metal, ammonium. I (R1 = C7H15; R2 = C2H4OC2H4; R3 = H; l = 5.9; m = 0; n = 1; L = OC6H4SO3Na) was used with Na percarbonate.

IT 213693-39-1 213693-40-4 213693-49-3
 213693-50-6
 RL: NUU (Other use, unclassified); USES (Uses)
 (bleach activators and bleach compns. containing the same, showing high bleaching powder for both hydrophilic and hydrophobic soils without discoloring the substrate)

RN 213693-39-1 CAPLUS


CN 10,13,16,19,22-Pentaoxa-7,25-diazahentriacontanedioic acid, 11,21-dioctyl-8,24-dioxo-, 1,31-bis(4-sulfophenyl) ester, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A




● 2 Na

PAGE 1-B




RN 213693-40-4 CAPLUS
 CN 10,13,16,19-Tetraoxa-7,22-diazaoctacosanedioic acid,
 11,18-dioctyl-8,21-dioxo-, bis(4-carboxyphenyl) ester, disodium salt (9CI)
 (CA INDEX NAME)

PAGE 1-A






● 2 Na




PAGE 1-B



RN 213693-49-3 CAPLUS
 CN 10,13,16,19-Tetraoxa-7,22-diazaoctacosanedioic acid,
 11,18-bis[(octyloxy)methyl]-8,21-dioxo-, 1,28-bis(4-sulfophenyl) ester,
 sodium salt (1:2) (CA INDEX NAME)



RN 213693-50-6 CAPLUS
 CN 10,13,16,19-Tetraoxa-7,22-diazaoctacosanedioic acid,
 11,18-bis[(octyloxy)methyl]-8,21-dioxo-, bis(4-carboxyphenyl) ester,
 disodium salt (9CI) (CA INDEX NAME)



L5 ANSWER 25 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1998:498186 CAPLUS
 DOCUMENT NUMBER: 129:204465
 ORIGINAL REFERENCE NO.: 129:41499a,41502a
 TITLE: Cleaning agent compositions based on amide ether
 carboxylic acid salts
 INVENTOR(S): Ota, Atsushi; Akasaki, Sayumi
 PATENT ASSIGNEE(S): Sanyo Chemical Industries Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
 CODEN: JKXXAF

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10204493	A	19980804	JP 1997-20093	19970117
JP 2964226	B2	19991018		

PRIORITY APPLN. INFO.: JP 1997-20093 19970117

AB Title cleaning compns., suitable for shampoo and body shampoo, comprise 70-97 weight% of amide ether carboxylic acid salt R1CONHCHR2CH2O(AO)nCH2CO2M (R1 = C6-24 fatty acid residue; R2 = H, C1-4 alkyl; A = C2-4 alkylene; n = 0-20; M = H, alkali metal, alkali earth metal, ammonium, low alkanolamine cation, basic amino acid cation), 2.5-15 weight% of polyoxyalkylene fatty acid alkanol amide R1CONHCHR2CH2O(AO)nH, 0.1-10 weight% of R1CO2M, and 0.005-5 weight% of oxy acids and/or their salts.


IT 186907-11-9

RL: TEM (Technical or engineered material use); USES (Uses)
(cleaning agent compns. based on amide ether carboxylic acid salts)

RN 186907-11-9 CAPLUS

CN 3,6,9,12-Tetraoxa-15-azaheptacosanoic acid, 16-oxo-, potassium salt (1:1)
(CA INDEX NAME)

PAGE 1-A



● K

PAGE 1-B

— (CH₂)₁₀—Me

L5 ANSWER 26 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:446868 CAPLUS

DOCUMENT NUMBER: 129:189581

ORIGINAL REFERENCE NO.: 129:38517a,38520a

TITLE: Ligand Recognition by E- and P-Selectin: Chemoenzymic Synthesis and Inhibitory Activity of Bivalent Sialyl Lewis x Derivatives and Sialyl Lewis x Carboxylic Acids

AUTHOR(S): Wittmann, Valentin; Takayama, Shuichi; Gong, Ke Wei; Weitz-Schmidt, Gabriele; Wong, Chi-Huey

CORPORATE SOURCE: Department of Chemistry and The Skaggs Institute for Chemical Biology, Scripps Research Institute, La Jolla, CA, 92037, USA

SOURCE: Journal of Organic Chemistry (1998), 63(15), 5137-5143
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 129:189581

AB Described is the preparation of five sialyl Lewis x (sLex) dimers and five sLex carboxylic acids by coupling chemoenzymically synthesized amino-substituted sLex to homo-bifunctional cross-linkers of varying chain length. The products were assayed for inhibition against binding of a sLea-polymer to immobilized E- and P-selectin. In the E-selectin assay all dimers had lower IC50 values than the sLex monomer. The results show that comparable binding enhancements can be obtained with linkers of completely different length and rigidity. In the P-selectin assay four of the five sLex carboxylic acids displayed significantly improved inhibitory potency. The lowest IC50 value was observed for the compound with the shortest spacer between the sLex moiety and the addnl. carboxylate, being ca. 20-40 times more potent than unmodified sLex. These findings should be of importance for the design of new multivalent forms of sLex as well as sLex mimetics as high-affinity selectin ligands.

IT	211746-89-3P	211746-90-6P	211746-91-7P
	211746-92-8P	211746-93-9P	211746-94-0P
	211746-96-2P	211746-97-3P	


RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (chemoenzymic synthesis and E- and P-selectin inhibitory activity of bivalent sialyl Lewis x derivs.)

RN 211746-89-3 CAPLUS


CN 3,6,9,12-Tetraoxatetradecanedi-
N,N'-bis[2-[6-[O-(N-acetyl- α -neuraminyloxy)-(2 \rightarrow 3)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 3)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyloxy]-1-oxohexyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 2-B






RN 211746-90-6 CAPLUS
 CN 3,6,9,12-Tetraoxa-15,18-diazatetracosanoic acid,
 24-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-
 galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-
 (1 \rightarrow 3)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.








RN 211746-91-7 CAPLUS

CN 3,6,9,12,15-Pentaoxaheptadecanediamide,
N,N'-bis[2-[[6-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-
galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-
(1 \rightarrow 3)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-1-
oxohexyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 211746-92-8 CAPLUS
 CN 3,6,9,12,15-Pentaoxa-18,21-diazaheptacosanoic acid,
 27-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-
 galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-
 (1 \rightarrow 3)]-2-(acetyl-amino)-2-deoxy- β -D-glucopyranosyl]oxy]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.






RN 211746-93-9 CAPLUS
 CN 3,6,9,12,15,18-Hexaoxaeicosanedi-
 amide,
 N,N'-bis[2-[[6-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-
 galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-
 (1 \rightarrow 3)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-1-
 oxohexyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




PAGE 1-B




PAGE 1-C




PAGE 2-B






RN 211746-94-0 CAPLUS
 CN 3,6,9,12,15,18-Hexaoxa-21,24-diazatriacontanoic acid,
 30-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-
 galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-
 (1 \rightarrow 3)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.








—CO₂H

RN 211746-96-2 CAPLUS
 CN 3,6,9,12,15,18,21-Heptaooxatricosanediamide,
 N,N'-bis[2-[[6-[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-
 galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-
 (1 \rightarrow 3)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-1-
 oxohexyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 211746-97-3 CAPLUS
 CN 3,6,9,12,15,18,21-Heptaosa-24,27-diazatritriacontanoic acid,
 33-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-
 galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-

Absolute stereochemistry.

The chemical structure shows a complex oligosaccharide composed of several pyranose rings linked by various glycosidic bonds. The structure includes several stereocenters marked with 'R' and 'S' configurations. Key features include:

- A terminal unit on the left with an AcNH group and a HO_2C group.
- A central unit with a Me group and a OH group.
- A unit with an NHAc group.
- A long fatty acid chain attached to the rightmost unit, represented as $(\text{CH}_2)_5$ followed by a carbonyl group and a terminal group.

[illegible]CCOC(=O)O

OS.CITING REF COUNT: 32 THERE ARE 32 CAPLUS RECORDS THAT CITE THIS
RECORD (33 CITINGS)
REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:212246 CAPLUS

DOCUMENT NUMBER: 128:286280

ORIGINAL REFERENCE NO.: 128:56585a,56588a

TITLE: Synthesis and characterization of
polymer-(multi)-peptide conjugates for control of
specific cell aggregation

AUTHOR(S): Belcheva, Nadya; Baldwin, Samuel P.; Saltzman, W. Mark

CORPORATE SOURCE: Sch. of Chem. Eng., Cornell Univ., Ithaca, NY, 14853,
USA

SOURCE: Journal of Biomaterials Science, Polymer Edition
(1998), 9(3), 207-226

CODEN: JBSEEA; ISSN: 0920-5063

PUBLISHER: VSP BV

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A new synthetic approach has been applied to obtain novel di-, tetra-, and
multi-peptide-containing polymer conjugates in quant. yields with a high degree
of conjugation. Bis(N-hydroxysuccinimidyl) esters of PEG (Mw = 200, 600,
1400, 2000, and 3400) were synthesized and studied in a condensation
reaction with synthetic peptides: glycine-glycine-tyrosine-arginine
(GGYR), a model peptide, and glycine-arginine-glycine-aspartic
acid-tyrosine (GRGDY), a sequence known to promote cell adhesion and
aggregation. Tetrasubstituted derivs. of PEG-based conjugates were
synthesized by coupling L-aspartic acid and L-aspartyl-L-phenylalanine
through a condensation procedure in organic media. Acrylic acid polymers (Mw
= 2000 and 5000) were studied as a model of multifunctional linear
polymers in the reaction with L-tryptophan and GGYR. Alternative
polymer-(multi)-peptide conjugates were successfully synthesized using a
polyamino-polyamide starburst dendrimer PAMAM (G = 3), 'short' and
'long'-chain PEG-based active esters and GRGDY. The structure of the
intermediate precursors and peptide-conjugates was confirmed by spectral
(UV-visible, FTIR, 1H-NMR) and chromatog. (RP-HPLC and SEC) methods. By
varying the properties of the interconnecting polymer - such as
hydrophobicity, mol. weight, and functionality - a set of polymer-GRGDY
conjugates was synthesized.

IT 205874-57-3P 205874-58-4P 205874-59-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)


(preparation and properties of polymer-peptide conjugates for cell
aggregation control)

RN 205874-57-3 CAPLUS


CN L-Arginine, 1,1'-(1,14-dioxo-3,6,9,12-tetraoxatetradecane-1,14-
diyl)bis[glycylglycyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




RN 205874-58-4 CAPLUS
 CN L-Tyrosine, 1,1'-(1,14-dioxo-3,6,9,12-tetraoxatetradecane-1,14-diyl)bis[glycyl-L-arginylglycyl-L- α -aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




RN 205874-59-5 CAPLUS
 CN L-Tyrosine, N-(17-hydroxy-16-methyl-1,14-dioxo-3,6,9,12-tetraoxa-15-
 azaheptadec-1-yl)glycyl-L-arginylglycyl-L- α -aspartyl-, 1,1'-diether
 with α -hydro- ω -hydroxypoly(oxy-1,2-ethanediyl) (9CI) (CA
 INDEX NAME)


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 1-D



PAGE 1-E



OS.CITING REF COUNT: 26 THERE ARE 26 CAPLUS RECORDS THAT CITE THIS RECORD (26 CITINGS)
 REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

DOCUMENT NUMBER: 128:76867
ORIGINAL REFERENCE NO.: 128:15013a,15016a
TITLE: Storage-stable cleaning compositions showing less trace after wiping for cleaning rigid surface
INVENTOR(S): Tsukuda, Kazunori; Suzuki, Satoru
PATENT ASSIGNEE(S): Kao Corp., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09310091	A	19971202	JP 1996-126996	19960522
PRIORITY APPLN. INFO.:			JP 1996-126996	19960522

OTHER SOURCE(S): MARPAT 128:76867

AB Title compns., useful for cleaning bathrooms, toilet bowls, kitchens, etc., comprise (A) MO₂CCHRN(CH₂CO₂M)₂ (I; R = C1-18 alkyl, alkenyl; M = H, Na, K, NH₄) or their salts 0.1-30, (B) surfactants 0.1-30, and (C) H₂O-soluble solvents 0.1-50% at B/C ratio 5/1 to 1/50. Thus, a composition comprising I (R = Me; M = Na) 3, decyltrimethylammonium chloride 4, diethylene glycol monobutyl ether 5, and H₂O to 100% showed good detergency and storage stability.


IT 200558-86-7

RL: TEM (Technical or engineered material use); USES (Uses)
(storage-stable compns. containing alkylglycine diacetates and surfactants for cleaning rigid surface)

RN 200558-86-7 CAPLUS


CN Propanoic acid, 2-oxo-3-[(13-oxo-3,6,9-trioxa-12-azatetracos-1-yl)oxy]-, sodium salt (1:1) (CA INDEX NAME)

PAGE 1-A



● Na

PAGE 1-B



L5 ANSWER 29 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:731708 CAPLUS

DOCUMENT NUMBER: 128:39384

ORIGINAL REFERENCE NO.: 128:7639a,7642a

TITLE: Liquid- or paste-type pearly cleanser compositions containing amido ether derivatives and (poly)alkylene glycol fatty acid esters

INVENTOR(S): Isobe, Kazuo

PATENT ASSIGNEE(S): Kao Corp., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09291017	A	19971111	JP 1996-102450	19960424
PRIORITY APPLN. INFO.:			JP 1996-102450	19960424

OTHER SOURCE(S): MARPAT 128:39384

AB Liquid- or paste-type pearly cleanser compns. contain amido ether derivs. and (poly)alkylene glycol fatty acid esters. The compns. show high-temperature stability and good appearance. A shampoo contained POE lauryl ether sulfate sodium salt 16, coco fatty acid amidopropylbetaine 3, cationic guar gum 0.2, stearyltrimmonium chloride 0.1, amido ether derivs., alkylene glycol fatty acid esters and ion-exchanged water to 100 weight%.

IT 170023-47-9

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)


(liquid- or paste-type pearly cleanser compns. containing amido ether derivs.

and polyalkylene glycol fatty acid esters)

RN 170023-47-9 CAPLUS

CN 3,6,9,12-Tetraoxa-15-azaheptacosanoic acid, 16-oxo-, sodium salt (1:1)
 (CA INDEX NAME)

PAGE 1-A



● Na

PAGE 1-B

— (CH₂)₁₀—Me

L5 ANSWER 30 OF 82 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:618994 CAPLUS

DOCUMENT NUMBER: 127:294996

ORIGINAL REFERENCE NO.: 127:57635a, 57638a

TITLE: Liquid detergent compositions containing amide ether carboxylic acids and amide ethers

INVENTOR(S): Nakagaki, Kiyoko; Sekiguchi, Takashi; Nozaki, Toshio

PATENT ASSIGNEE(S): Kao Corp., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09241679	A	19970916	JP 1996-47165	19960305
PRIORITY APPLN. INFO.:			JP 1996-47165	19960305
OTHER SOURCE(S): MARPAT 127:294996				

AB The title compns. with pH 7.0-9.3, showing good foamability to give skin-compatible creamy foam, contain (A) $\geq 50\%$ -solids 99:1-10:90 mixts. of R1CONR2(CH₂CH₂O)nCH₂CO₂M (salts) and R1CONR3(CH₂CH₂O)nH containing $\leq 5\%$ R4OCH₂CHOR4CH₂OR4 [R1 = C5-23 linear or branched alkyl, alkenyl, alk(en)yl-substituted Ph; R2 = H, (CH₂CH₂O)nCH₂CO₂M, (CH₂CH₂O)mH, C1-3 alkyl; M = H, alkali metal, alkaline earth metal, ammonium, alkanolamine, basic amino acid residue; m, n = 1-20; R3 = (CH₂CH₂O)mH, C1-3 alkyl; R4 = H, (CH₂CH₂O)nCH₂CO₂M, (CH₂CH₂O)mH], (B) fatty acid (salts), and (C) NaOH, KOH, or triethanolamine. Thus, 1 mol Me laurate and 1.02 mol H₂NCH₂CH₂OH reacted in the presence of NaOMe in MeOH in vacuo at 90° for 5 h and treated with 2 mol ethylene oxide at 100-110° to give a reaction mixture which (331 g) was treated with 174.8 g ClCH₂CO₂Na in alkaline condition to give 85:15 mixture of C₁₁H₂₃CONH(CH₂CH₂O)₃CH₂CO₂Na and C₁₁H₂₃CONH(CH₂CH₂O)₃H. A composition (5% aqueous solution, pH 8.2) comprising 8% of


the above mixture, 2% lauric acid, 1.05% KOH (48% aqueous solution) and balance H₂O showed good foamability in washing body.

IT 175699-67-9P 175699-68-0P
 RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (liquid detergents containing mixts. of amide ether carboxylic acids and amide ethers showing good foamability)


RN 175699-67-9 CAPLUS

CN 3,6,9,12,15-Pentaoxa-18-azatriacontanoic acid, 19-oxo-, sodium salt (1:1)
 (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



RN 175699-68-0 CAPLUS

CN 3,6,9,12,15,18-Hexaoxa-21-azapentatriacontanoic acid, 22-oxo-, sodium salt (1:1) (CA INDEX NAME)



=> s 15 and spacer

66090 SPACER

L6 9 L5 AND SPACER

=> d 16 ibib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y/(N):y

L6 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:708816 CAPLUS

DOCUMENT NUMBER: 137:247925

TITLE: Preparation of peptide nucleic acid (PNA) containing fluorescence and/or biotin-labeled puromycin derivatives as their use for C-terminus monomolecular labeling of proteins

INVENTOR(S): Sasaki, Akira; Nemoto, Naoto

PATENT ASSIGNEE(S): Gencom Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002265492	A	20020918	JP 2001-65257	20010308
PRIORITY APPLN. INFO.:			JP 2001-65257	20010308
OTHER SOURCE(S):	MARPAT	137:247925		

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Puromycin derivs. [I; R = R1-L1-, X-L3-L2-L1-, X1-L8-L7-L6-CH(-L5-L9-L10-L11-L12-L13-X2)-L4-L3-L2-L1-; wherein L1, L3, L6, L9, L11, L13 = a spacer; L2, L4, L5, L7, L10, L12 = a linkage group; R1 = a reactive group; Nu = pyrimidine or purine base residue such as cytosine; X1, X2 = a residue of a labeling substance such as a fluorescence substance] are prepared Also disclosed are protein or nucleic acid or derivative thereof containing the compound I or its salt as the

constituent component. Claimed is a method for preparation of modified protein or nucleic acid involving a process of allowing the compound I or its salt to be taken up into the protein or nucleic acid. The present patent establishes the efficient synthesis of puromycin derivs. which are used to efficiently label protein at the C-terminus, and a method for forming a complex of nucleic acid and a protein coded by the nucleic acid using the puromycin derivs. A protein introduced with the puromycin derivative I is typically prepared by introducing RNA (preferably mRNA) coding the protein and the puromycin derivative I into a transcription system and transcribing RNA into protein. Thus, N-trifluoroacetylation of puromycin by trifluoroacetic anhydride in pyridine/MeCN followed by tosylation with tosyl chloride in pyridine gave N α -trifluoroacetyl-5'-O-tosyl puromycin which underwent azidolysis with NaN₃ in DMSO at room temperature for

3

days to give N α -trifluoroacetyl-5'-azido-5'-deoxy puromycin (II). Reduction of II to N α -trifluoroacetyl-5'-amino-5'-deoxy puromycin by treatment with Ph₃P and H₂O in pyridine followed by condensation with N-[2-(4-methoxytritylamino)ethyl]-N-[[N4-(4-tert-butylbenzoyl)cytosin-1-yl]acetyl]glycine pentafluorophenyl ester in 0.15 M NaHCO₃/Na₂CO₃ buffer and deprotection with NH₃ in aqueous EtOH and then with CF₃CO₂H gave I (R = H₂N-CH₂CH₂, Nu = cytosin-1-yl) which was condensed with FluoroLink Mono Reactive Dye Cy5 to give I (R = Q) (Cy5-C-amPu). mRNA coding green fluorescein protein (GFP) (1 μ g) and 10 μ M I (R = Q) were added to 50 μ L of a wheat germ noncellular translation system (Promega) and allowed to react for 1 h. It was confirmed by separation of the protein using SDS-polyacrylamide electrophoresis and detecting the both fluorescein from I (R = Q) and GFP that the GFP synthesized was labeled by I (R = Q).

IT 459426-24-5P

RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptide nucleic acid (PNA) containing fluorescence and/or biotin-labeled puromycin derivs. as use for C-terminus monomol.



labeling of proteins and nucleic acids by translation of RNA into proteins)



RN 459426-24-5 CAPLUS

CN Adenosine, 3'-[[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-5'-[[[[[(4-amino-2-oxo-1(2H)-pyrimidinyl)acetyl][2-[[N-[21-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1,17-dioxo-4,7,10,13-tetraoxa-16-azaheneicos-1-yl]- β -alanyl-N6-[6-[2-[(1E,3E,5E)-5-(1-ethyl-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene)-1,3-pentadienyl]-3,3-dimethyl-5-sulfo-3H-indolio]-1-oxohexyl]-L-lysyl- β -alanyl]amino]ethyl]amino]acetyl]amino]-3',5'-dideoxy-N,N-dimethyl-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.






IT 459426-22-3, (+)-Biotin-PEO4-NHS-propionate
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of peptide nucleic acid (PNA) containing fluorescence and/or
 biotin-labeled puromycin derivs. as use for C-terminus monomol.
 labeling of proteins and nucleic acids by translation of RNA into
 proteins)
 RN 459426-22-3 CAPLUS
 CN 4,7,10,13-Tetraoxa-16-azaheneicosanoic acid,
 21-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-17-oxo-,
 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)


Absolute stereochemistry.








IT	459426-23-4P 459426-25-6P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of peptide nucleic acid (PNA) containing fluorescence and/or biotin-labeled puromycin derivs. as use for C-terminus monomol. labeling of proteins and nucleic acids by translation of RNA into proteins)
RN	459426-23-4 CAPLUS
CN	Adenosine, 3'-[[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-5'-[[[[[(4-amino-2-oxo-1(2H)-pyrimidinyl)acetyl][2-[[N-[21-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1,17-dioxo-4,7,10,13-tetraoxa-16-azaheneicos-1-yl]-β-alanyl-L-lysyl-β-alanyl]amino]ethyl]amino]acetyl]amino]-3',5'-dideoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 459426-25-6 CAPLUS

CN Adenosine, 3'-[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-5'-[[[[(4-amino-2-oxo-1(2H)-pyrimidinyl)acetyl][2-[[N-[21-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1,17-dioxo-4,7,10,13-tetraoxa-16-azaheneicos-1-yl]-β-alanyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-β-alanyl]amino]ethyl]amino]acetyl]amino]-3',5'-dideoxy-N,N-dimethyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:266161 CAPLUS

DOCUMENT NUMBER: 137:29586

TITLE: Replacement of the intervening amino acid sequence of
a Syk-binding diphosphopeptide by a nonpeptide
spacer with preservation of high affinity

AUTHOR(S): Dekker, Frank J.; de Mol, Nico J.; van Ameijde,
Jeroen; Fischer, Marcel J. E.; Ruijtenbeek, Rob;
Redegeld, Frank A. M.; Liskamp, Rob M. J.

CORPORATE SOURCE: Department of Medicinal Chemistry Utrecht Institute of
Pharmaceutical Sciences, Utrecht University, Utrecht,
3508 TB, Neth.

SOURCE: ChemBioChem (2002), 3(2-3), 238-242

CODEN: CBCHFX; ISSN: 1439-4227

PUBLISHER: Wiley-VCH Verlag GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A high-affinity compound was constructed by linking two relatively weakly
interacting monophosphorylated peptides by an oligoethylene glycol
spacer. To prepare the required spacers, hexa- and tetraethylene
glycol were converted into amino acid superstructures.
Benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate,
N,N-diisopropylethylamine, and 9-fluorenylmethyloxycarbonyl amino acids
were used for the couplings. The tandem Src homol.-2 (SH2) domain of
murine Syk was cloned, expressed, and purified to determine the affinity of the
phosphopeptides and the phosphopeptide hybrids for the Syk tandem SH2
domain. In the surface plasmon resonance (SPR) assay, the peptide
featuring the immunoreceptor tyrosine-based activation motif sequence was
extended with an N-terminal 6-aminohexanoic acid moiety to provide a
spacer between the SPR sensor chip and the peptide. The mol.
construct with the hexaethylene glycol spacer showed an affinity
comparable to the native diphosphorylated ITAM peptide. The results
indicated that a nonpeptide spacer can substitute the
intervening amino acids in the native Syk tandem SH2 domain binding
ligand.


IT 437655-98-6P 437655-99-7P

RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic
preparation); BIOL (Biological study); PREP (Preparation)
(diphosphopeptide analog; oligoethylene glycol derivative spacer
preparation and use in linking monophosphorylated peptides in relation to
Syk kinase SH2 domain binding)

RN 437655-98-6 CAPLUS

CN L-Leucinamide, N-acetyl-O-phosphono-L-tyrosyl-L-threonylglycyl-L-leucyl-20-
amino-3,6,9,12,15,18-hexaoxaecosanoyl-O-phosphono-L-tyrosyl-L- α -
glutamyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 437655-99-7 CAPLUS



CN L-Leucinamide, N-acetyl-O-phosphono-L-tyrosyl-L-threonylglycyl-L-leucyl-14-amino-3,6,9,12-tetraoxatetradecanoyl-O-phosphono-L-tyrosyl-L- α -glutamyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







IT 391684-35-8P 437655-94-2P 437655-95-3P
 437655-96-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; oligoethylene glycol derivative spacer preparation and
 use in linking monophosphorylated peptides in relation to Syk kinase
 SH2 domain binding)
 RN 391684-35-8 CAPLUS
 CN 5,8,11,14,17,20-Hexaoxa-2-azadocosanedioic acid,
 1,22-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 437655-94-2 CAPLUS
 CN 5,8,11,14-Tetraoxa-2-azahexadecanedioic acid, 1,16-bis(1,1-dimethylethyl)
 ester (CA INDEX NAME)



PAGE 1-B




RN 437655-95-3 CAPLUS
CN 5,8,11,14-Tetraoxa-2-azahexadecanedioic acid, 1-(9H-fluoren-9-ylmethyl)
ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 437655-96-4 CAPLUS
CN 5,8,11,14,17,20-Hexaoxa-2-azadocosanedioic acid, 1-(9H-fluoren-9-ylmethyl)
ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS
RECORD (18 CITINGS)

L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:52907 CAPLUS
DOCUMENT NUMBER: 134:277052
TITLE: Cell-surface recognition of biotinylated membrane
proteins requires very long spacer arms: an

example from glucose-transporter probes
 AUTHOR(S): Hashimoto, Makoto; Yang, Jing; Holman, Geoffrey D.
 CORPORATE SOURCE: Department of Biology and Biochemistry, University of
 Bath, Bath, BA2 7AY, UK
 SOURCE: ChemBioChem (2001), 2(1), 52-59
 Published in: Angew. Chem., Int. Ed., 40(1)
 CODEN: CBCHFX; ISSN: 1439-4227
 PUBLISHER: Wiley-VCH Verlag GmbH
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 134:277052

AB Glucose transporters (GLUTs) can be photoaffinity labeled by
 (diazirinetrifluoroethyl)benzoyl-substituted glucose derivs. and the
 adduct can be recognized, after detergent solubilization of membranes, by
 using streptavidin-based detection systems. However, in intact cells
 recognition of photolabeled GLUTs by avidin and anti-biotin antibodies
 only occurs if the bridge between the photoreactive and the biotin
 moieties has a min. of 60-70 spacer atoms. We show that a
 suitably long bridge can be synthesized with a combination of polyethylene
 glycol and tartrate groups and that introduction of these spacers
 generates hydrophilic products that can be cleaved with periodate.
 Introduction of the very long spacers does not appreciably reduce the
 affinity of interaction of the probes with the transport system.



IT 332941-37-4P 332941-54-5P 332941-56-7P
 RL: PNU (Preparation, unclassified); RCT (Reactant); PREP (Preparation);
 RACT (Reactant or reagent)
 (reagents with long spacer arms between biotin and
 photoaffinity label can be used for cell-surface recognition of
 biotinylated glucose transporters)


RN 332941-37-4 CAPLUS

CN D-Glucose, 4-O-[24-carboxy-2-[[4-[3-(trifluoromethyl)-3H-diazirin-3-
 yl]benzoyl]amino]-4,7,10,13,16,19,22-heptaooxatetracos-1-yl]- (CA INDEX
 NAME)

Absolute stereochemistry.

PAGE 1-A








RN 332941-54-5 CAPLUS

CN D-Glucose, 4-O-[62-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-25,51,58-trioxo-2-[[4-[3-(trifluoromethyl)-3H-diazirin-3-yl]benzoyl]amino]-4,7,10,13,16,19,22,29,32,35,38,41,44,47-tetradeca-26,50,57-triazadohexacont-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-C




PAGE 1-D




RN 332941-56-7 CAPLUS
 CN D-Glucose, 4-O-[(31R,32R)-63-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-31,32-dihydroxy-25,30,33,59-tetraoxo-2-[[4-[3-(trifluoromethyl)-3H-diazirin-3-yl]benzoyl]amino]-4,7,10,13,16,19,22,37,40,43,46,49,52,55-tetradeca-26,29,34,58-tetraazatrihexacont-1-yl]]- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 1-C





PAGE 1-D





IT 332941-34-1P 332941-35-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(reagents with long spacer arms between biotin and
photoaffinity label can be used for cell-surface recognition of
biotinylated glucose transporters)
RN 332941-34-1 CAPLUS
CN D-Glucose, 4-O-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-27,27-dimethyl-25-
oxo-4,7,10,13,16,19,22,26-octaaoctacos-1-yl]-2,3:5,6-bis-O-(1-
methylethylidene)-, 1-(dimethyl acetal) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 332941-35-2 CAPLUS
 CN D-Glucose, 4-O-[24-carboxy-2-[[(1,1-dimethylethoxy)carbonyl]amino]-
 4,7,10,13,16,19,22-heptaooxatetracos-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 32 THERE ARE 32 CAPLUS RECORDS THAT CITE THIS
 RECORD (32 CITINGS)
 REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1998:446868 CAPLUS
 DOCUMENT NUMBER: 129:189581
 ORIGINAL REFERENCE NO.: 129:38517a,38520a



TITLE: Ligand Recognition by E- and P-Selectin: Chemoenzymic Synthesis and Inhibitory Activity of Bivalent Sialyl Lewis x Derivatives and Sialyl Lewis x Carboxylic Acids
 AUTHOR(S): Wittmann, Valentin; Takayama, Shuichi; Gong, Ke Wei; Weitz-Schmidt, Gabriele; Wong, Chi-Huey
 CORPORATE SOURCE: Department of Chemistry and The Skaggs Institute for Chemical Biology, Scripps Research Institute, La Jolla, CA, 92037, USA
 SOURCE: Journal of Organic Chemistry (1998), 63(15), 5137-5143
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 129:189581




AB Described is the preparation of five sialyl Lewis x (sLex) dimers and five sLex carboxylic acids by coupling chemoenzymically synthesized amino-substituted sLex to homo-bifunctional cross-linkers of varying chain length. The products were assayed for inhibition against binding of a sLea-polymer to immobilized E- and P-selectin. In the E-selectin assay all dimers had lower IC50 values than the sLex monomer. The results show that comparable binding enhancements can be obtained with linkers of completely different length and rigidity. In the P-selectin assay four of the five sLex carboxylic acids displayed significantly improved inhibitory potency. The lowest IC50 value was observed for the compound with the shortest spacer between the sLex moiety and the addnl. carboxylate, being ca. 20-40 times more potent than unmodified sLex. These findings should be of importance for the design of new multivalent forms of sLex as well as sLex mimetics as high-affinity selectin ligands.

IT 211746-89-3P 211746-90-6P 211746-91-7P
 211746-92-8P 211746-93-9P 211746-94-0P
 211746-96-2P 211746-97-3P
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (chemoenzymic synthesis and E- and P-selectin inhibitory activity of bivalent sialyl Lewis x derivs.)

RN 211746-89-3 CAPLUS
 CN 3,6,9,12-Tetraoxatetradecanediamide,
 N,N'-bis[2-[[6-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 3)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-1-oxohexyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 211746-90-6 CAPLUS
 CN 3,6,9,12-Tetraoxa-15,18-diazatetracosanoic acid,
 24-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-
 galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-
 (1 \rightarrow 3)]]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






PAGE 1-B



RN 211746-91-7 CAPLUS

CN 3,6,9,12,15-Pentaoxaheptadecanediamide,
N,N'-bis[2-[[6-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-
galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-
(1 \rightarrow 3)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-1-
oxohexyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 211746-92-8 CAPLUS
 CN 3,6,9,12,15-Pentaoxa-18,21-diazaheptacosanoic acid,
 27-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-
 galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-


(1→3)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







PAGE 1-B



RN 211746-93-9 CAPLUS
CN 3,6,9,12,15,18-Hexaoxaeicosanediamide,
N,N'-bis[2-[[6-[[O-(N-acetyl-α-neuraminosyl)-(2→3)-O-β-D-
galactopyranosyl-(1→4)-O-[6-deoxy-α-L-galactopyranosyl-
(1→3)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-1-
oxohexyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 211746-94-0 CAPLUS
 CN 3,6,9,12,15,18-Hexaoxa-21,24-diazatriacontanoic acid,
 30-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-
 galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-
 (1 \rightarrow 3)]]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C


—CO₂H

RN 211746-96-2 CAPLUS
 CN 3,6,9,12,15,18,21-Heptaosaxatricosanediamide,
 N,N'-bis[2-[[6-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-


galactopyranosyl-(1→4)-O-[6-deoxy- α -L-galactopyranosyl-(1→3)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-1-oxohexyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




RN 211746-97-3 CAPLUS
 CN 3,6,9,12,15,18,21-Hepta-oxa-24,27-diazatritriacontanoic acid,
 33-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-
 galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-
 (1 \rightarrow 3)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





OS.CITING REF COUNT: 32 THERE ARE 32 CAPLUS RECORDS THAT CITE THIS
RECORD (33 CITINGS)
REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:575490 CAPLUS

DOCUMENT NUMBER: 127:216547

ORIGINAL REFERENCE NO.: 127:42045a, 42048a

TITLE: Formation of Microscale Gradients of Protein Using
Heterobifunctional Photolinkers

AUTHOR(S): Hypolite, Claire L.; McLernon, Terri L.; Adams, Derek
N.; Chapman, Kenneth E.; Herbert, Curtis B.; Huang, C.
C.; Distefano, Mark D.; Hu, Wei-Shou

CORPORATE SOURCE: Department of Chemical Engineering and Materials
Science, University of Minnesota, Minneapolis, MN,
55455-0132, USA

SOURCE: Bioconjugate Chemistry (1997), 8(5), 658-663
CODEN: BCCHE; ISSN: 1043-1802

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 127:216547

AB Gradients of biol. mols. on a microscale have been postulated to elicit cellular responses, such as migration. However, it has been difficult to prepare such gradients for exptl. testing. A means for producing such gradients has been developed using a heterobifunctional photolinking agent with laser light activation. The photolinking agent synthesized includes an N-hydroxysuccinimide group and a photoreactive benzophenone (BP) separated by a tetraethylene glycol (TEG) spacer. The presence of the tetraethylene glycol spacer renders the photolinker hydrophilic, a desirable trait for conjugation in aqueous solns. The linker was then conjugated to R-phycoerythrin (R-PE), a fluorescent protein. The resulting photolinker-R-phycoerythrin conjugate (BP-TEG-PE) was then immobilized onto a polystyrene surface by laser irradiation on a motorized stage. By varying exposure time of the sample to the beam, the amount of BP-TEG-PE immobilized on the surface was changed over an order of magnitude over a distance of 250 μm . This method can be applied to prepare gradients of proteins that elicit biol. responses, such as extracellular matrix proteins or growth factors, and to study the biol. effects of such gradients.


IT 195071-53-5P 195071-55-7DP, reaction products with
phycoerythrin

RL: PEP (Physical, engineering or chemical process); PRP (Properties); RCT
(Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC
(Process); RACT (Reactant or reagent)


(formation of microscale gradients of protein using heterobifunctional
photolinkers)


RN 195071-53-5 CAPLUS
 CN Acetic acid, 2-[[13-(4-benzoylphenyl)-13-oxo-3,6,9-trioxa-12-azatridec-1-yl]oxy]-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

PAGE 1-A





PAGE 2-A







RN 195071-55-7 CAPLUS
 CN 3,6,9,12-Tetraoxatetradecanamide, 14-[(4-benzoylbenzoyl)amino]- (CA INDEX NAME)




IT 195071-49-9P 195071-51-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (formation of microscale gradients of protein using heterobifunctional photolinkers)
 RN 195071-49-9 CAPLUS
 CN Acetic acid, 2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]- (CA INDEX NAME)



RN 195071-51-3 CAPLUS
 CN Acetic acid, 2-[[13-(4-benzoylphenyl)-13-oxo-3,6,9-trioxa-12-azatridec-1-yl]oxy]- (CA INDEX NAME)





OS.CITING REF COUNT: 58 THERE ARE 58 CAPLUS RECORDS THAT CITE THIS RECORD (58 CITINGS)
 REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:516284 CAPLUS

DOCUMENT NUMBER: 125:247294

ORIGINAL REFERENCE NO.: 125:46221a,46224a

TITLE: Syntheses of ligands containing two and three 2,2'-(bisamino)diphenyl ether units designed for molecular self-assembly on lithiation

AUTHOR(S): Ashton, Peter R.; Hoerner, Bernd; Kocian, Oldrich; Menzer, Stephan; White, Andrew J. P.; Stoddart, J. Fraser; Williams, David J.

CORPORATE SOURCE: School Chem., Univ. Birmingham, Birmingham, B15 2TT, UK

SOURCE: Synthesis (1996), (8), 930-940

CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Thieme

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The syntheses of polyamines containing 2-3 2,2'-(bisamino)diphenyl ether units linked together, designed for self-assembly following lithiation, are reported. The x-ray crystal structures of 2 of the bis[2,2-(bisamino)diphenyl ethers] are described. The ligand, which is linked by an ethylene glycol spacer, exhibits a coiled conformation by intramol. H bonds and supplemented by [CH- π] interactions. The ligand, which is linked by a more rigid bridge, containing a paraphenylene unit, displays a stretched conformation stabilized by intramol. edge to face interactions.


IT 181725-32-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of ligands with (bisamino)diphenyl ether units)

RN 181725-32-6 CAPLUS

CN 3,6,9,12-Tetraoxatetradecanediamide,
 N1,N14-bis[2-[2-[(2-methoxyacetyl)amino]phenoxy]phenyl]- (CA INDEX NAME)





OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(8 CITINGS)

L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:551679 CAPLUS

DOCUMENT NUMBER: 121:151679

ORIGINAL REFERENCE NO.: 121:27289a, 27292a

TITLE: On the lipid head group hydration of floating surface monolayers bound to self-assembled molecular protein layers

AUTHOR(S): Loesche, Mathias; Erdelen, Christian; Rump, Elmar; Ringsdorf, Helmut; Kjaer, Kristian; Vaknin, David

CORPORATE SOURCE: Institute of Physical Chemistry, Johannes-Gutenberg-Universitaet Mainz, Mainz, D-55099, Germany

SOURCE: Thin Solid Films (1994), 242(1-2), 112-17
CODEN: THSFAP; ISSN: 0040-6090

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The structure of monomol. layers of the protein streptavidin, specifically bound to biotin-functionalized lipid monolayers at aqueous surfaces, has been characterized. Neutron and x-ray reflectivity measurements allowed an assessment of the organization of these self-assembled systems with mol. resolution. Emphasis here is placed on the hydration of the lipid head groups in the bound state. For three functionalized lipids with spacers of different lengths between the biotin and their chains it was observed that the head groups were dehydrated in monolayers of the pure lipids, which were kept at low surface pressure before protein adsorption. The introduction of dipole moments at the interface by the admixt. of phospholipids or the application of lateral pressure on the lipid monolayer before protein adsorption were found to impose an extension of the spacer moieties. The biotin groups were thus presented further away from the interface, and a hydration layer between the protein and the functionalized interface was observed in the self-assembled supramol. structures.

IT 157300-02-2D, complexes with streptavidin

RL: BIOL (Biological study)
(membrane monolayer, lipid head group hydration in)

RN 157300-02-2 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide,
hexahydro-N-(24-octadecyl-23-oxo-3,6,9,12,15,18,21-hepta-oxa-24-
azadotetracont-1-yl)-2-oxo-, [3aS-(3a α ,4 β ,6 α)]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

ACCESSION NUMBER: 1993:656373 CAPLUS

DOCUMENT NUMBER: 119:256373

ORIGINAL REFERENCE NO.: 119:45621a, 45624a

TITLE: Preparation and characterization of conjugates of monoclonal antibodies and staphylococcal enterotoxin A using a new hydrophilic crosslinker

AUTHOR(S): Aakerblom, Eva; Dohlsten, Mikael; Brynoe, Charlotte;
Mastej, Maria; Steringer, Ingrid; Hedlund, Gunnar;
Lando, Peter; Kalland, Terje

CORPORATE SOURCE: Kabi Pharm. AB, Uppsala, S-751 82, Swed.

SOURCE: Bioconjugate Chemistry (1993), 4(6), 455-66

CODEN: BCCHES; ISSN: 1043-1802

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Conjugates between monoclonal antibodies recognizing human cancer cells and the superantigen staphylococcal enterotoxin A (mAb-SEA) represent a potential novel approach to tumor therapy. Such mAb-SEA conjugates direct T-cells to lyse colon carcinoma cells in vitro. The synthesis of mAb-SEA conjugates which were prepared by introducing thiol groups on SEA and iodoacetyl or maleimide groups on mAb forming a stable thioether linkage between SEA and mAb is described. A hydrophilic spacer, composed of repeated ethylene oxide units, was constructed to increase the distance between SEA and mAb, preserving biol. activity of both proteins. The degree of modification of mAb with rSEA was determined with SDS-PAGE. Variables influencing the composition of the conjugates and their effect on the tumor-cell cytotoxicity were studied and optimal conditions for the synthesis were established. Functionally active mAb-SEA conjugates were prepared from a panel of different mAb and T-cell-dependent cytotoxicity against several human cancer types including colon, ovarian, breast, and renal cancer was obtained. Thus, mAb-SEA conjugates may be of value of the treatment of human neoplastic disease.


IT 141282-23-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(hydrolysis of)


RN 141282-23-7 CAPLUS

CN 3,6,9,12,15-Pentaoxaheptadecanoic acid, 17-amino-, 1-methylethyl ester
(CA INDEX NAME)

PAGE 1-A



PAGE 1-B




IT 141282-33-9DP, reaction products with crosslinked Staphylococcal enterotoxin A derivs. 141282-38-4DP, reaction products with crosslinked monoclonal antibody derivs. 151225-48-8DP, reaction products with crosslinked Staphylococcal enterotoxin A derivs. RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and characterization of)


RN 141282-33-9 CAPLUS

CN Acetic acid, 2-[(17-iodo-16-oxo-3,6,9,12-tetraoxa-15-azaheptadec-1-yl)oxy]-
, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 141282-38-4 CAPLUS

CN	Acetic acid, 2-[[16-oxo-18-(2-pyridinyldithio)-3,6,9,12-tetraoxa-15-azaoctadec-1-yl]oxy]-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)
----	---

PAGE 1-A




PAGE 1-B




RN 151225-48-8 CAPLUS
 CN 3,6,9,12,15-Pentaoxa-18-azaheneicosanoic acid,
 21-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-19-oxo-,
 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




IT 141282-34-0P 141282-37-3P 151225-46-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and esterification with hydroxysuccinimide)
 RN 141282-34-0 CAPLUS
 CN Acetic acid, 2-[(17-iodo-16-oxo-3,6,9,12-tetraoxa-15-azaheptadec-1-yl)oxy]-
 (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 141282-37-3 CAPLUS
 CN Acetic acid, 2-[[16-oxo-18-(2-pyridinyldithio)-3,6,9,12-tetraoxa-15-

azaoctadec-1-yl]oxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 151225-46-6 CAPLUS
CN 3,6,9,12,15-Pentaoxa-18-azaheneicosanoic acid,
21-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-19-oxo- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




IT 151225-47-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction with succinimidyl alkanoate derivs.)
RN 151225-47-7 CAPLUS
CN Acetic acid, 2-[(14-amino-3,6,9,12-tetraoxatetradec-1-yl)oxy]-,
hydrochloride (1:1) (CA INDEX NAME)



PAGE 1-A





● HCl





IT 141282-33-9P 141282-38-4P 151225-48-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 141282-33-9 CAPLUS
 CN Acetic acid, 2-[(17-iodo-16-oxo-3,6,9,12-tetraoxa-15-azaheptadec-1-yl)oxy]-
 , 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)



RN 141282-38-4 CAPLUS
 CN Acetic acid, 2-[[16-oxo-18-(2-pyridinyldithio)-3,6,9,12-tetraoxa-15-
 azaoctadec-1-yl]oxy]-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)



RN 151225-48-8 CAPLUS
 CN 3,6,9,12,15-Penta-oxa-18-azaheneicosanoic acid,
 21-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-19-oxo-,
 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)



L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1991:143917 CAPLUS

DOCUMENT NUMBER: 114:143917

ORIGINAL REFERENCE NO.: 114:24441a, 24444a

TITLE: Preparation of cobalamin acid hydrazides and their conjugates for immunological analysis

INVENTOR(S): Huber, Erasmus; Dieckhoff, Josef; Klein, Christian; Kuerzinger, Konrad

PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H., Germany

SOURCE: Ger. Offen., 12 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3900648	A1	19900712	DE 1989-3900648	19890111
US 5171679	A	19921215	US 1990-461215	19900105
EP 378203	A2	19900718	EP 1990-100462	19900110
EP 378203	A3	19921014		
EP 378203	B1	19960828		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL				
AT 141926	T	19960915	AT 1990-100462	19900110
JP 02233693	A	19900917	JP 1990-2635	19900111
JP 07017672	B	19950301		

PRIORITY APPLN. INFO.: DE 1989-3900648 A 19890111


OTHER SOURCE(S): CASREACT 114:143917; MARPAT 114:143917

AB Stable B-CONHNH(X-CONHNH)x-H (B = cobalamin residue minus one CONH2 group; X = spacer; x = 0, 1), whose conjugates with enzymes are useful for immunol. anal., especially in immunoassays for the determination of cyanocobalamin,

were prepared Cyanocobalamin-8-acid in DMF-H2O was treated with N-hydroxysuccinimide and NaCN, the solution was adjusted to pH 5.5 with NaOH, N-ethyl-N'-[3-(dimethylamino)propyl]carbodiimide-HCl and H2NNHCOCH2(OCH2CH2)3OCH2ONHNH2-HCl were added, and the reaction mixture was allowed to react to give cyanocobalamin-8-acid N'-[[2-[2-[2-(hydrazinocarbonylmethoxy)ethoxy]ethoxy]ethoxy]acetyl]hydrazide. A conjugate of this with horseradish peroxidase was more effective and simpler to use for the immunoassay of vitamin B12 than the known

cyanocobalamin-8-acid-horseradish peroxidase conjugate.
 IT 132684-10-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and condensation of, with cobalamin derivative)
 RN 132684-10-7 CAPLUS
 CN 3,6,9,12-Tetraoxatetradecanedioic acid, 1,14-dihydrazide, hydrochloride
 (1:2) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B


—NH₂

IT 132684-08-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and deprotection of, in preparation of cobalamin conjugate)
 RN 132684-08-3 CAPLUS
 CN 6,9,12,15-Tetraoxa-2,3,18,19-tetraazaeicosanedioic acid, 4,17-dioxo-,
 1,20-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



PAGE 1-A




PAGE 1-B



IT 132550-07-3DP, peroxidase conjugate 132550-07-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, for immunoassay of cyanocobalamins)
 RN 132550-07-3 CAPLUS
 CN Cobinamide, Co-(17-hydrazino-1,4,17-trioxo-6,9,12,15-tetraoxa-2,3-
 diazaheptadec-1-yl)-, dihydrogen phosphate (ester), inner salt, 3'-ester
 with (5,6-dimethyl-1- α -D-ribofuranosyl-1H-benzimidazole- κ N3)
 (9CI) (CA INDEX NAME)








ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 132550-07-3 CAPLUS

CN Cobinamide, Co-(17-hydrazino-1,4,17-trioxo-6,9,12,15-tetraoxa-2,3-diazaheptadec-1-yl)-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1- α -D-ribofuranosyl-1H-benzimidazole- κ N3) (9CI) (CA INDEX NAME)





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)